030419
PhosphoSitePlus(R) (PSP) was created by Cell Signaling Technology Inc. It is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. When using PSP data or analyses in printed publications or in online resources, the following acknowledgements must be included: (a) the words "PhosphoSitePlus(R), www.phosphosite.org" must be included at appropriate places in the text or webpage, and (b) the following citation must be included in the bibliography: "Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015 43:D512-20. PMID: 25514926."

DISEASE	ALTERATION	GENE	PROTEIN	ACC_ID	GENE_ID	HU_CHR_LOC	MW_kD	ORGANISM	SITE_GRP_ID	MOD_RSD	DOMAIN	SITE_+/-7_AA	PMIDs	LT_LIT	MS_LIT	MS_CST	CST_CAT#	NOTES	
Alzheimer's disease	mutation of site	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	16554819	36	5	3	6986; 3823	Pin1 binds to the pT668-Pro motif but not when mutated to Ala. 
endometrial cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16585156	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
endometrial cancer	increased	Esr1	ER-alpha	P19785	13982	10 A1|10 2.03 cM	66.95	mouse	448102	S171-p	Oest_recep	NGRERLSsSNEKGNM	16585156	38	5	0	42101; 64508	
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12244301	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	Expression of phosphorylated S473 in invasive breast carcinomas correlates with cytosolic p27.  
acute myelogenous leukemia	deletion of site	Myb	Myb	P06876	17863	10 A3|10 9.75 cM	71.42	mouse	448186	S11-p		RPRHSIYsSDEDDED	2157164	5	1	1		
acute myelogenous leukemia	deletion of site	Myb	Myb	P06876	17863	10 A3|10 9.75 cM	71.42	mouse	448187	S12-p		PRHSIYSsDEDDEDI	2157164	5	1	2		
Alzheimer's disease	increased	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	14970211	36	5	3	6986; 3823	
Alzheimer's disease	increased	APLP2	APLP2	Q06481	334	11q24.3	86.96	human	451599	T736-p	APP_amyloid	VEVDPMLtPEERHLN	14970211	3	2	1		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448413	S310-p	Androgen_recep	TEDTAEYsPFKGGYT	12015328	10	5	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449805	S16-p	Androgen_recep	RVYPRPPsKTYRGAF	12015328	4	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448414	S651-p		GEASSTTsPTEETTQ	12015328	8	3	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449807	S426-p	Androgen_recep	AAGPGSGsPSAAASS	12015328	3	1	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	449806	S258-p	Androgen_recep	VEALEHLsPGEQLRG	12015328	3	2	1		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	12015328	8	10	0		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	12015328	14	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	12118371	82	2	0	2511	
small-cell lung cancer	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	16705183	163	4	0	2661; 2197; 12812	
acute lymphocytic leukemia; chronic myelogenous leukemia; leukemia	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448586	S62-p	Myc_N	LLPTPPLsPSRRSGL	16855632	52	33	33	13748	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447583	T41-p		GIHSGATtTAPSLSG	11955436	59	3	0	4270; 13537; 9561; 9565	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447582	S37-p		YLDSGIHsGATTTAP	11955436	70	3	12	4270; 2009; 13537; 9561	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	11955436	28	6	0	19807; 70034; 9565; 9564	
colorectal cancer	mutation of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	11955436	67	3	2	4270; 2009; 13537; 9561	
Alzheimer's disease	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448513	S222-p	Pkinase	LIDSMANsFVGTRSY	17064357	108	18	203	2338; 9154; 16211; 9121; 3958	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447741	S259-p		SQRQRSTsTPNVHMV	17064357	50	31	142	9421	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447742	S338-p		RPRGQRDsSYYWEIE	17064357	81	2	7	9427	
Alzheimer's disease	increased	MAP2K1	MEK1	Q02750	5604	15q22.31	43.44	human	448514	S218-p	Pkinase	VSGQLIDsMANSFVG	17064357	112	12	83	9154; 9121; 3958	
Alzheimer's disease	increased	MAP2K2	MEK2	P36507	5605	19p13.3	44.42	human	448074	S226-p	Pkinase	LIDSMANsFVGTRSY	17064357	55	18	201	2338; 9154; 16211; 9121; 3958	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447750	Y341-p		GQRDSSYyWEIEASE	17064357	33	1	1		
Alzheimer's disease	increased	MAP2K2	MEK2	P36507	5605	19p13.3	44.42	human	448073	S222-p	Pkinase	VSGQLIDsMANSFVG	17064357	58	12	83	9154; 9121; 3958	
Alzheimer's disease	increased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447749	Y340-p		RGQRDSSyYWEIEAS	17064357	26	1	1		
colorectal carcinoma	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	17148760	344	100	3046	6943; 2101	colon adenocarcinoma
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	448201	T729-p	APP_amyloid	MLKKKQYtSIHHGVV	17634293	4	0	0		
Bloom's syndrome	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	17634426	166	22	4	13050; 4526; 5883	
lung cancer	mutation of site	Ccne1	CCNE1	Q61457	12447	7 B3|7 25.35 cM	46.99	mouse	447676	T393-p		PPPSVVLtPPPSSKK	16023597	15	10	0		experimental mutation of site to alanine increased tumorigenesis in p53 knockout mice and susceptibility to Ras-induced lung cancer
ischemia	increased	Camk2a	CAMK2A	P11275	25400	18q12.1	54.11	rat	447797	T286-p		SCMHRQEtVDCLKKF	14687884	126	30	72	12716	
ischemia	increased	Gria1	GluR1	P19490	50592	10q22	101.58	rat	467226	S836-p		CYKSRSEsKRMKGFC	14687884	6	0	0		
rhabdomyosarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17848913	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
rhabdomyosarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17848913	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15467756	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10866684	56	37	30		
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15743786	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	15743786	24	0	1		
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448781	T198-p		PGLRRRQt_______	15743786	25	0	6		
non-small cell lung adenocarcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448059	Y1172-p		ISLDNPDyQQDFFPK	18687633	43	57	967	4404	
non-small cell lung adenocarcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	18687633	114	27	352	2236; 3777; 2234; 14565; 8543	
Down syndrome	increased	CRYAB	CRYAB	P02511	1410	11q23.1	20.16	human	448783	S59-p		PSFLRAPsWFDTGLS	19272359	42	20	0		in the brain tissues isolated from children and young adults
Down syndrome	increased	CRYAB	CRYAB	P02511	1410	11q23.1	20.16	human	448748	S45-p	Crystallin	FPTSTSLsPFYLRPP	19272359	34	7	1		in the brain tissues isolated from children and young adults
Hodgkin's lymphoma	increased	TRAF2	TRAF2	Q12933	7186	9q34.3	55.86	human	7378202	S55-p	zf-C3HC4	QCGHRYCsFCLASIL	19336568	2	0	0		constitutive phosphorylation
PSP	decreased	TH	TH iso3	P07101-3	7054	11p15.5	55.61	human	448544	S31-p	TOH_N	KQAEAIMsPRFIGRR	9920892	37	7	0	3370; 13041	TH isoform lacking S31 and S40 is overexpressed in PSP patients
PSP	decreased	TH	TH iso3	P07101-3	7054	11p15.5	55.61	human	448545	S40-p	TOH_N	RFIGRRQsLIEDARK	9920892	54	10	11	2791	TH isoform lacking S31 and S40 is overexpressed in PSP patients
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	447737	S890-p		ITSTLASsFKRRRSS	19283475	12	1	3	3381	
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	448256	S897-p		SFKRRRSsKDTSTGG	19283475	26	0	0	3385	
Parkinson's disease	decreased	Grin1	NMDAR1	P35439	24408	3p13	105.51	rat	448255	S896-p		SSFKRRRsSKDTSTG	19283475	22	0	0	3384	
prostate cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	19147545	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449132	S701-p		DTSPRHLsNVSSTGS	10460255	13	9	5		
Alzheimer's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447929	S506-p		GSRSRTPsLPTPPTR	10460255	46	19	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	8318230	116	41	90	9632	
Alzheimer's disease	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	8930358	4	6	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	12766916	86	37	14		potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	12766916	70	26	33	29957	potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.
Alzheimer's disease; FTLD	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	15136685	42	29	23	12885	increased in early-onset Alzheimer disease patients, as compared to  frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455736	S117-p	Osteopontin	DVDDTDDsHQSDESH	19775205	1	3	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455739	S126-p	Osteopontin	QSDESHHsDESDELV	19775205	1	4	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455737	S120-p	Osteopontin	DTDDSHQsDESHHSD	19775205	1	3	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455738	S123-p	Osteopontin	DSHQSDEsHHSDESD	19775205	1	4	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
X-linked hypophosphatemia	increased	SPP1	osteopontin	P10451	6696	4q22.1	35.42	human	455740	S129-p	Osteopontin	ESHHSDEsDELVTDF	19775205	1	4	0		ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH
hepatitis	decreased	FOXO1	FOXO1A	Q12778	2308	13q14.11	69.66	human	448075	S256-p		SPRRRAAsMDNNSKF	18316359	77	6	48	84192; 9461	nonalcoholic steatohepatitis (NASH)
hepatitis	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	18316359	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	nonalcoholic steatohepatitis (NASH)
Kaposi's sarcoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	448515	T199-p		VKKSIRDtPAKNAQK	20333249	20	27	30	3541	
atrial fibrillation	increased	RYR2	RYR2	Q92736	6262	1q43	564.57	human	458801	S2814-p		ISQTSQVsVDAAHGY	20056922	43	6	5		
kidney cancer	increased; translocation	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448130	S166-p		SSRRRAIsETEENSD	19920202	39	19	5	3521	nuclear localization
sporadic inclusion-body myositis	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	19878439	74	125	4206		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	19940156	38	5	0	42101; 64508	high S167 phosphorylation in tamoxifen resistant tumors
lymphoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	20224723	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	mantle cell lymphoma, 67% of tumors showed positive S9 phosphorylation.
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	20179234	17	0	0		
Parkinson's disease	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19800394	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	11321358	K221-ac	Enolase_C	APNILENkEGLELLK	20433201	1	6	1		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146804	K105-ac	Enolase_N	DGTENKSkFGANAIL	20433201	0	1	2		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	474652	K285-ac	Enolase_C	DLYKSFIkDYPVVSI	20433201	0	2	1		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146808	K262-ac	Enolase_C	GKYDLDFkSPDDPSR	20433201	0	1	2		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146803	K103-ac	Enolase_N	EMDGTENkSKFGANA	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146801	K28-ac	Enolase_N	EVDLFTSkGLFRAAV	20433201	0	2	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146806	K239-ac	Enolase_C	GKAGYTDkVVIGMDV	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	14146807	K330-ac	Enolase_C	TNPKRIAkAVNEKSC	20433201	0	1	0		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	461589	K256-ac	Enolase_C	SEFFRSGkYDLDFKS	20433201	1	8	31		sites phosphorylated in pancreatic ductal adenocarcinoma (PDAC) cells and not in normal pancreatic duct cells
prostate cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	14515900	Y176-p	Pkinase	EKATGRYyAMKILKK	20333297	2	1	0		murine prostatic intraepithelial neoplasia (mPINs)
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	14515900	Y176-p	Pkinase	EKATGRYyAMKILKK	20333297	2	1	0		
breast cancer	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	450946	Y284-p	Pkinase_Tyr	LPQNDDHyVMQEHRK	20333297	6	27	235	3138	
HIV Encephalitis	increased	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	458211	Y1325-p	NMDAR2_C	RLLEGNFyGSLFSVP	20448061	4	2	84		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448100	S106-p	Oest_recep	PLNSVSPsPLMLLHP	20418363	22	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	449929	T311-p		NSLALSLtADQMVSA	20418363	7	0	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	20418363	38	5	0	42101; 64508	S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048401	S282-p		EGRGEVGsAGDMRAA	20418363	4	0	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048400	S559-p	ESR1_C	PTSRGGAsVEETDQS	20418363	4	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	451560	S294-p		RAANLWPsPLMIKRS	20418363	10	3	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448099	S104-p	Oest_recep	FPPLNSVsPSPLMLL	20418363	22	1	0		S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	20418363	82	2	0	2511	S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. 
Wilm's tumor	deletion of site	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447488	S45-p		GATTTAPsLSGKGNP	12239584	28	6	0	19807; 70034; 9565; 9564	Observed frequent mutations of S45 of beta-catenin in Wilm's tumors.
ataxia-telangiectasic cancer	decreased	SMC1A	Smc1	Q14683	8243	Xp11.22	143.23	human	448698	S966-p	SMC_N	GEDSVSGsQRISSIY	12447382	19	14	67		
Fanconi's anaemia		FANCG	FANCG	O15287	2189	9p13.3	68.55	human	453422	S7-p		_MSRQTTsVGSSCLD	15299017	2	1	0		
breast cancer	increased	AKT2	Akt2	P31751	208	19q13.2	55.77	human	448520	S474-p	Pkinase_C	RTHFPQFsYSASIRE	11507039	20	8	55	88106; 9271; 3787; 4060; 5315; 9563; 4070; 15116; 4051; 5102; 4075; 5012; 4071; 8599; 4058; 11962; 2336; 2337; 12694	
medullary thyroid carcinoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455479	Y791-p	Pkinase_Tyr	HPHVIKLyGACSQDG	15753368	2	0	0		
medullary thyroid carcinoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455478	S891-p	Pkinase_Tyr	EGRKMKIsDFGLSRD	15753368	1	0	0		
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	15757972	15	25	3		
Xeroderma pigmentosum	mutation of site	RARA	RARA	P10276	5914	17q21.2	50.77	human	455459	S77-p		EIVPSPPsPPPLPRI	11955452	9	2	0		
chronic myelogenous leukemia		RB1	Rb	P06400	5925	13q14.2	106.16	human	456752	Y805-p	Rb_C	RIPGGNIyISPLKSP	16158058	1	2	37		phosphorylation of this site has a positive role in survival of Bcr/Abl-positive CML cells
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	459012	K303-ac		LMIKRSKkNSLALSL	15604293	5	0	0		
esophageal cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	Pkinase_Tyr	DEAYVMAsVDNPHVC	16357520	4	0	0		
congenital progressive hydronephrosis	mutation of site	Aqp2	AQP2	P56402	11827	15 F1|15 56.13 cM	28.96	mouse	449854	S256-p		REVRRRQsVELHSPQ	16641094	69	7	0		in mice
rheumatoid arthritis	increased	NCF1	p47phox	P14598	653361	7q11.23	44.68	human	451727	S345-p		QARPGPQsPGSPLEE	16778989	12	7	0		TAT-Ser345 peptide (ARPGPQSPGSPL) may have potenital antiinflammatory properties
synucleinopathy	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	16847063	42	5	0	23706	
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467290	S2524-p	DUF3454	PDQWSSSsPHSNVSD	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467289	S2523-p	DUF3454	SPDQWSSsSPHSNVS	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467288	S2522-p	DUF3454	ESPDQWSsSSPHSNV	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
acute lymphocytic leukemia	deletion of site	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	467287	S2521-p	DUF3454	PESPDQWsSSSPHSN	16880534	1	0	0		mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL
ataxia-telangiectasic cancer	decreased	RFWD2	COP1	Q8NHY2	64326	1q25.1-q25.2	80.47	human	467307	S387-p		SDDSRTAsQLDEFQE	16931761	3	0	1		alternation: mutation of ATM protein kinase 
Alzheimer's disease; schizophrenia	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448555	S25-p	Stathmin	QAFELILsPRSKESV	16925597	45	116	91		increased in some schizophrenic patients; decreased in patients with Alzheimer's disease
Alzheimer's disease; schizophrenia	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	16925597	43	108	166	4191; 3426	increased in some schizophrenic patients; not significantly changed in patients with the Alzheimer's disease
type 2 diabetes	decreased	Vasp	VASP	B5DEX4	361517	1q21	39.72	rat	448381	T274-p		LARRRKAtQVGEKPP	17082196	9	3	19		
type 2 diabetes	decreased	Vasp	VASP	B5DEX4	361517	1q21	39.72	rat	448380	S236-p		GAKLRKVsKEEASGG	17082196	46	26	3	3114	
type 2 diabetes	decreased	Prkaa1	AMPKA1	P54645	65248	2q16	63.97	rat	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	17082196	207	14	33	5256; 2535; 4188; 50081; 2531	
Cowden disease	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	472273	S552-p		QDTQRRTsMGGTQQQ	17237784	15	59	9	9566; 5651	observed in PTEN mouse mutant
Parkinson's disease	decreased	PRKN	PARK2	O60260	5071	6q26	51.64	human	454421	S131-p		HTDSRKDsPPAGSPA	17327227	3	1	0		
atherosclerosis	decreased	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448403	S82-p		RALSRQLsSGVSEIR	15249501	57	98	289	9709; 2406; 2401; 11892	
ataxia-telangiectasia	decreased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	9733515	401	7	0	9235; 8695; 9284; 9286; 8514; 12571; 4030	
breast cancer	increased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447831	S280-p		AKRPRVTsGGVSESP	17418864	11	26	145	2347	
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	455575	S664-p	Tuberin	KKTSGPLsPPTGPPG	17671177	7	9	1	40729	
glioblastoma multiforme	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448055	Y1016-p		DVVDADEyLIPQQGF	17575160	43	6	12	2235	
Parkinson's disease	increased	Snca	SNCA	O55042	20617	6 B3|6 29.15 cM	14.49	mouse	448278	S129-p	Synuclein	SEAYEMPsEEGYQDY	17360705	42	5	0	23706	
type 2 diabetes	decreased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	17130464	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	17130464	137	22	277	8566; 9337; 9316; 9331; 5090; 9327; 8452	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17130464	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Tbc1d4	AS160	Q8BYJ6	210789	14|14 E2.3	147.45	mouse	455921	T649-p		QFRRRAHtFSHPPSS	17130464	34	20	134	8881; 4288	using high fat diet-induced insulin resistance in mice as a model.
type 2 diabetes	decreased	Akt1s1	PRAS40	Q9D1F4	67605	7|7 B3	27.48	mouse	470067	T247-p	PRAS	LPRPRLNtSDFQKLK	17130464	33	66	781	13175; 2640; 2997	using high fat diet-induced insulin resistance in mice as a model.
colorectal cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	478351	S252-p		ASAHRKSsSSSGDPS	17371847	3	1	3		In cancers where Erk1/2 is upregulated
colorectal cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	478352	S265-p		PSSDPLGsPTLLAL_	17371847	3	8	6	3880; 5841	In cancers where Erk1/2 is upregulated
leukemia	decreased	MYB	Myb	P01103	396244		72.47	chicken	448757	S116-p	Myb_DNA-binding	KYGPKRWsVIAKHLK	12456674	1	0	0		AMV virus-induced monocytic leukemia has a v-Myb V117D mutation which inhibits phosphorylation of S116.
nephrosis	increased	Kirrel1	KIRREL	Q6X936	310695	2q34	87.24	rat	463752	Y638-p		KDPTNGYyNVRAHED	18258597	2	5	49		
nephrosis	increased	Kirrel1	KIRREL	Q6X936	310695	2q34	87.24	rat	463751	Y637-p		MKDPTNGyYNVRAHE	18258597	2	12	84		
vesicoureteral reflux	mutation of site	RET	Ret iso2	P07949-2	5979	10q11.21	119.85	human	2246703	G691-p		PVSYSSSgARRPSLD	18273880	1	0	0		mutation of G691 to serine due to SNP
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	14579119	42	5	0	23706	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	16645045	46	19	42	77348	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048401	S282-p		EGRGEVGsAGDMRAA	19104930	4	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	11943712	102	48	69	35834; 20194	S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. useful diagnostic marker of AD
diabetes mellitus	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17272402	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
diabetes mellitus	decreased	INSR	INSR	P06213	3643	19p13.2	156.33	human	1012666	Y1149-p	Pkinase_Tyr	EIADGMAyLNAKKFV	17272402	1	1	1		
nephrogenic diabetes insipidus	decreased	AQP2	AQP2	P41181	359	12q13.12	28.84	human	449854	S256-p		REVRRRQsVELHSPQ	16120822	69	7	0		
myxoid liposarcoma	translocation	FUS	hnRNP P2	P35637	2521	16p11.2	53.43	human	3306333	S42-p		QQSYSGYsQSTDTSG	18620545	6	2	0		t(12;16)(q13;p11) translocation
cardiomyopathy	mutation of site	Creb1	CREB	Q01147	12912	1 C2|1 32.74 cM	36.67	mouse	448228	S133-p	pKID	EILSRRPsYRKILND	17616745	245	4	61	9187; 4095; 9196; 9198; 14228; 14001	
stroke	decreased	NOS3	eNOS	Q7YSG7	397557		133.33	pig	447884	S1179-p		TSRIRTQsFSLQERH	17557122	157	15	7	9571; 9570	
atherosclerosis	decreased	Nos3	eNOS	P70313	18127	5 A3|5 11.32 cM	132.92	mouse	467802	S1178-p		RIRTQSFsLQERQLR	17982133	8	6	1		
fibrosarcoma of soft tissue	mutation of site	MMP14	MMP14	P50281	4323	14q11.2	65.89	human	478362	Y573-p	DUF3377	GTPRRLLyCQRSLLD	18621744	7	3	39		experimental mustation of site interferes with tumor cell proliferation and tumor growth
breast cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18353781	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
testicular cancer	increased	H2AFX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	15846060	195	29	29	2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312	
testicular cancer	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	15846060	166	22	4	13050; 4526; 5883	
DCM	decreased	HSPB6	HSP20	O14558	126393	19q13.12	17.14	human	450706	S16-p	Crystallin	PSWLRRAsAPLPGLS	18790732	19	27	2		in patients carrying P20L substitution in Hsp20 
breast cancer	increased	Ncoa3	SRC-3	O09000	17979	2|2 H3	151.57	mouse	4668109	Y1331-p		HPQPTPMyQPSDMKG	18765637	1	1	0		
non-melanoma skin cancer	increased	Jun	Jun	P05627	16476	4 C5|4 43.34 cM	35.94	mouse	447686	S63-p	Jun	KNSDLLTsPDVGLLK	10851065	110	41	4	9261; 5464; 2361	
non-melanoma skin cancer	increased	Jun	Jun	P05627	16476	4 C5|4 43.34 cM	35.94	mouse	447943	S73-p	Jun	VGLLKLAsPELERLI	10851065	73	64	16	8752; 9164; 3270; 12714	
chronic lymphocytic leukemia	increased	PRKCD	PKCD	Q05655	5580	3p21.1	77.51	human	447511	T507-p	Pkinase	FGESRAStFCGTPDY	12393602	42	20	108	9379; 9374; 93292; 2060; 38938	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	449929	T311-p		NSLALSLtADQMVSA	19104930	7	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	11943712	116	41	90	9632	S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. useful diagnostic marker of AD
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	19104930	82	2	0	2511	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	19104930	38	5	0	42101; 64508	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448100	S106-p	Oest_recep	PLNSVSPsPLMLLHP	19104930	22	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	6048400	S559-p	ESR1_C	PTSRGGAsVEETDQS	19104930	4	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448099	S104-p	Oest_recep	FPPLNSVsPSPLMLL	19104930	22	1	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	451560	S294-p		RAANLWPsPLMIKRS	19104930	10	3	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	18656473	35	1	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	18656473	35	1	0		
breast cancer	increased	YBX1	YB-1	P67809	4904	1p34.2	35.92	human	455636	S102-p	CSD	NPRKYLRsVGDGETV	19036157	9	32	2	2900	
lung cancer	mutation of site	Ptk2	FAK iso2	P34152-2	14083	15 D3|15 33.94 cM	122.77	mouse	447966	Y956-p	Focal_AT	DRSNDKVyENVTGLV	18606490	85	17	427	3284	regulates metastasis and invasion
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	19235466	35	1	0		phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	19235466	35	1	0		phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	8858002	102	48	69	35834; 20194	Guam ALS/parkinsonism-dementia complex
lymphoma	increased	PTPN11	SHP-2	Q06124	5781	12q24.13	68.44	human	448493	Y584-p		REDSARVyENVGLMQ	17483340	16	60	1189	5431; 3703; 13328	Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations
lymphoma	increased	PTPN11	SHP-2	Q06124	5781	12q24.13	68.44	human	448492	Y546-p		SKRKGHEyTNIKYSL	17483340	27	24	442	3751	Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations
myopathy	mutation of site	DES	desmin	P17661	1674	2q35	53.54	human	466346	S13-p	Filament_head	SSSQRVSsYRRTFGG	18061454	2	0	0		
diabetes mellitus	increased	Aqp2	AQP2	P34080	25386	7q36	28.93	rat	449854	S256-p		REVRRRQsVELHSPQ	18029369	69	7	0		
breast cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	17495324	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	phosphorylation correlates with Mcl-1 and poor prognosis in breast cancer, in multiple cell lines and primary human cancer samples. 
hepatocellular carcinoma	increased	RXRA	RXRA	P19793	6256	9q34.2	50.81	human	450891	S260-p	Hormone_recep	NMGLNPSsPNDPVTN	11826406	9	1	0		
breast cancer; colorectal cancer	increased	CAV1	caveolin-1	Q03135	857	7q31.2	20.47	human	448422	Y14-p		VDSEGHLyTVPIREQ	18922892	40	44	830	3251	involved in metastasis
breast adenocarcinoma	mutation of site	Birc5	Survivin	O70201	11799	11|11 E2	16.30	mouse	447705	T34-p	BIR	FLEDCACtPERMAEA	18816410	13	6	7	8888	inhibition of growth and metastases
ventricular tachycardia; hypertrophic cardiomyopathy	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	3949250	T190-p	Pkinase	FLTEYVAtRWYRAPE	19060905	3	17	17		
ventricular tachycardia; hypertrophic cardiomyopathy	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	3949250	T188-p	Pkinase	FLTEYVAtRWYRAPE	19060905	3	17	17		
cervical squamous cell carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	19079619	129	14	106	2971; 5536; 2976	
cervical squamous cell carcinoma	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	19079619	361	6	1	9209; 9206; 97596; 9234; 9205	
lung cancer	increased	RASSF1	RASSF1 iso2	Q9NS23-2	11186	3p21.31	38.81	human	484000	S203-p	RA	TSVRRRTsFYLPKDA	19276349	8	8	1		
ischemia	increased	Golga3	GOLGA3	P55937	269682	5 F|5 53.36 cM	167.22	mouse	487482	S174-p		VKRHRERsSQPATKM	17888676	1	0	0		
ischemia	increased	Golga3	GOLGA3	P55937	269682	5 F|5 53.36 cM	167.22	mouse	478659	S385-p		EVRSRRDsICSSVSM	17888676	1	7	28		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	10211802	S221-p	Filament	DSLMDEIsFLKKVHE	19678766	0	1	0		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	10211801	S215-p	Filament	ELEKRIDsLMDEISF	19678766	0	1	1		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	3926308	S103-p	Filament	DLNDRFAsFIERVHE	19678766	0	4	1		
HAM/TSP	increased	NEFL	NFL	P07196	4747	8p21.2	61.52	human	450895	S472-p		EAKDEPPsEGEAEEE	19678766	2	18	0		
glioblastoma multiforme	decreased	CTNNA1	CTNNA1	P35221	1495	5q31.2	100.07	human	449139	S641-p	Vinculin	TPEELDDsDFETEDF	19941816	2	95	78		
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	448546	T1462-p		GLRPRGYtISDSAPS	12150915	52	13	48	3617; 3611	
tuberous sclerosis	increased	TSC2	TSC2	P49815	7249	16p13.3	200.61	human	448501	S939-p		SFRARSTsLNERPKS	12150915	19	31	50	3615	
Waardenburg syndrome type 2	mutation of site	MITF	MITF iso9	O75030-9	4286	3p13	46.94	human	448503	S298-p	DUF3371	QARAHGLsLIPSTGL	10587587	3	1	0		
leukemia	translocation	ABL1	Abl	P00519	25	9q34.12	122.87	human	450300	Y257-p	Pkinase_Tyr	GGQYGEVyEGVWKKY	15256422	4	13	323		
synucleinopathy; Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	12505616	42	5	0	23706	
Alzheimer's disease	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448358	T444-p		RFIGSPRtPVSPVKF	16364302	100	36	109	9204	p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains
Alzheimer's disease	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448357	S447-p		GSPRTPVsPVKFSPG	16364302	96	51	247	9204	p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains
cervical cancer	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448854	S282-p		TAPLSPMsPPGYKLV	15958277	31	7	1		
cervical cancer	increased	GJA1	GJA1	P17302	2697	6q22.31	43.01	human	448853	S279-p		SSPTAPLsPMSPPGY	15958277	32	6	1		
cystic fibrosis	decreased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447734	S53-p		ISVSRSTsFRGGMGS	16424149	16	12	14		increased phosphorylation caused by curcumin rescue of CFTR F508 deletion
ischemia	increased	Gabbr2	GABBR2	O88871	83633	5q22	105.75	rat	473060	S783-p		VTSVNQAsTSRLEGL	17224405	6	0	0		
leukemia	increased	ABL1	Abl	P00519	25	9q34.12	122.87	human	450300	Y257-p	Pkinase_Tyr	GGQYGEVyEGVWKKY	17164333	4	13	323		elevated in drug resistant leukemias with T315I mutations in Abl, and is associated with increased oncogenicity
Huntington's disease	decreased	Ppp1r1b	DARPP-32	Q60829	19049	11|11 D	21.78	mouse	448047	T34-p	DARPP-32	MIRRRRPtPAMLFRV	10829080	60	5	44	12438	decreased in Huntington's disease mouse model
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	11813001	42	5	0	23706	
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084635	S404-p		FNGGFGSsMDSKSSG	18546284	10	1	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084615	S379-p		NSYSGSNsGAAIGWG	18546284	4	1	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084617	S403-p		GFNGGFGsSMDSKSS	18546284	10	2	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	18546284	35	1	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	18546284	35	1	0		
mantle cell lymphoma	increased	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448130	S166-p		SSRRRAIsETEENSD	18467333	39	19	5	3521	
mantle cell lymphoma	increased	MDM2	MDM2	Q00987	4193	12q15	55.23	human	448131	S186-p		RQRKRHKsDSISLSF	18467333	12	8	2		
prostate cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	17045208	344	100	3046	6943; 2101	phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	470068	Y535-p		MDSYSGPyGDMRLET	17045208	3	1	0		phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448470	Y1234-p	Pkinase_Tyr	RDMYDKEyYSVHNKT	17062641	47	35	740	3129; 3077; 3126; 4091; 4033; 12468	
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448469	Y1003-p		VSNESVDyRATFPED	17062641	12	26	366	3135	
bladder cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448471	Y1235-p	Pkinase_Tyr	DMYDKEYySVHNKTG	17062641	45	16	442	3129; 3077; 3126; 4091; 4033; 12468	
cancer, squamous cell carcinoma	decreased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	16115915	19	0	0		
breast cancer	increased	PTK2B	Pyk2	Q14289	2185	8p21.2	115.87	human	447955	Y402-p		CSIESDIyAEIPDET	10713673	73	2	22	3291	breast carcinoma cell invasion
angiosarcoma	mutation of site	GJA4	GJA4	P35212	2701	1p34.3	37.41	human	3243300	P319-p		PPQNGQKpPSRPSSS	10728596	1	0	0		
ARVC	mutation of site	DSP	Desmoplakin	P15924	1832	6p24.3	331.77	human	3067800	S299-p		EELLYDWsDKNTNIA	12373648	1	0	0		
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	15502804	63	43	112	8974; 8957; 8516; 4277; 9308; 11917	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	448717	S811-p	Rb_C	IYISPLKsPYKISEG	15502804	62	38	80	8974; 8957; 8516; 4277; 9308; 11917	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
melanoma skin cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447979	S795-p	Rb_C	SPYKFPSsPLRIPGG	15502804	44	16	94	9301	phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15324364	86	37	14		AD diagnostic tool
myotonic dystrophy type1	increased	CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	18570922	3	8	1		indirect evidence - Akt site, and Akt activity increased in DM1
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	455495	S1387-p		EDCSGLSsQSDILTT	10866324	8	0	0		
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	448036	S1423-p		AVLEQHGsQPSNSYP	10866324	13	1	1		
ataxia-telangiectasia	decreased	BRCA1	BRCA1	P38398	672	17q21.31	207.72	human	450008	S1457-p		SEKAVLTsQKSSEYP	10866324	6	4	1		
ovarian cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	15208673	129	14	106	2971; 5536; 2976	
liver cancer	decreased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	457552	S193-p		PPPHPHAsPAHLAAP	15684384	12	0	0		
liver cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15684384	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
schizophrenia	mutation of site	SYN3	SYN3	O14994	8224	22q12.3	63.30	human	455901	S470-p		PQGQQPLsPQSGSPQ	15900227	2	7	9		
GIST	increased	KIT	Kit	P10721	3815	4q12	109.86	human	448017	Y721-p	Pkinase_Tyr	CSDSTNEyMDMKPGV	15007386	17	5	52	3391	
GIST	increased	KIT	Kit	P10721	3815	4q12	109.86	human	448016	Y703-p	Pkinase_Tyr	DHAEAALyKNLLHSK	15007386	5	4	22	3073	
nephrosis	decreased	Nphs1	NPHS1	Q9R044	64563	1q21	136.28	rat	469566	Y1228-p		CEDPRGIyDQVAADM	18256598	10	0	0		
nephrosis	decreased	Nphs1	NPHS1	Q9R044	64563	1q21	136.28	rat	469565	Y1204-p		PGAWGPLyDEVRMDP	18256598	14	1	0		
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	18315566	39	33	25		
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449130	S400-p		VYKSPVVsGDTSPRH	18315566	12	39	70	35834; 20194	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	18315566	105	49	116	39357	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	18315566	102	48	69	35834; 20194	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	18315566	86	37	14		
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	18315566	116	41	90	9632	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	18315566	4	27	26	35834; 20194	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	18315566	20	26	6		
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	18315566	42	29	23	12885	
PSP	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447926	S46-p		TDAGLKEsPLQTPTE	18315566	2	8	0		
breast adenocarcinoma	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	16461563	211	12	1	3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475	
kidney cancer	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448472	Y1349-p		STFIGEHyVHVNATY	16914575	27	6	125	3133; 3121	
chronic lymphocytic leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16940331	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
chronic lymphocytic leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	16940331	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
bipolar disprder	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	16806104	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
breast cancer	increased	MKNK1	Mnk1	Q9BUB5	8569	1p33	51.34	human	447622	T255-p	Pkinase	ITTPELTtPCGSAEY	17130135	12	1	0	2111; 43507	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	17157789	38	5	0	42101; 64508	
melanoma skin cancer	decreased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447754	Y701-p		DGPKGTGyIKTELIS	17785551	138	6	64	25809; 8009; 8062; 9174; 9167; 5375; 8183; 7649	
chronic myelogenous leukemia	increased	NBN	NBS1	O60934	4683	8q21.3	84.96	human	448605	S343-p		TTPGPSLsQGVSVDE	17431132	41	19	69	3001	
AIDS-related lymphoma	decreased	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	17310999	56	37	30		primary effusion lymphoma
breast cancer	increased	MKNK1	Mnk1	Q9BUB5	8569	1p33	51.34	human	447621	T250-p	Pkinase	NSCTPITtPELTTPC	17130135	13	1	1	2111; 43507	
colorectal carcinoma	decreased	SRC	Src	P12931	6714	20q11.23	59.83	human	448235	Y530-p		FTSTEPQyQPGENL_	17974954	126	24	968	2105; 2101	
prostate cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455680	T11-p	Histone	KQTARKStGGKAPRK	18066052	15	5	0	9767; 9764	
gastric carcinoma	mutation of site	TLR4	TLR4	O00206	7099	9q33.1	95.68	human	3597308	T175-p	LRR_8	PEYFSNLtNLEHLDL	16786156	1	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	17314187	42	29	23	12885	
retinitis pigmentosa	mutation of site	NRL	NRL	P54845	4901	14q11.2-q12	25.94	human	478419	S50-p		PYSSVPPsPTFSEPG	17335001	2	0	1		
breast cancer	mutation of site	BRCA2	BRCA2	P51587	675	13q13.1	384.20	human	455462	S3291-p		SPICTFVsPAAQKAF	15800615	7	1	0		
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12499277	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
ovarian cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15208673	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
ovarian cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15208673	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
bladder cancer	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	15361851	163	4	0	2661; 2197; 12812	
AIDS-related lymphoma; B cell lymphoma; Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10706881	56	37	30		
schizophrenia	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	14745448	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
T cell leukemia	mutation of site	TP53	p53	P04637	7157	17p13.1	43.65	human	447532	S37-p		NVLSPLPsQAMDDLM	11042698	68	3	0	9289	
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084601	S410-p		SSMDSKSsGWGM___	19125255	35	1	0		
FTLD; ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	19125255	35	1	0		
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448796	S255-p		ELSPTTLsPVNHSLD	19115199	6	0	0	3104	
hepatocellular carcinoma		ITGB1	ITGB1	P05556	3688	10p11.22	88.42	human	447709	T789-p	Integrin_b_cyt	IYKSAVTtVVNPKYE	19115199	10	2	1		
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448794	S245-p		NQSMDTGsPAELSPT	19115199	8	0	0	3104	
hepatocellular carcinoma		SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	448795	S250-p		TGSPAELsPTTLSPV	19115199	6	0	0	3104	
hepatocellular carcinoma		ITGB1	ITGB1	P05556	3688	10p11.22	88.42	human	448600	T788-p	Integrin_b_cyt	PIYKSAVtTVVNPKY	19115199	11	1	1		
prostate cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	18829527	145	53	67	9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994	
type 2 diabetes	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	12765939	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
type 2 diabetes	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447506	S636-p		SGDYMPMsPKSVSAP	12765939	37	23	1	2388	
type 2 diabetes	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	12765939	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
type 2 diabetes	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	12765939	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
type 2 diabetes	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	12765939	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
Lafora disease		PPP1R3C	PPP1R3C	Q9UQK1	5507	10q23.32	36.45	human	6423500	S33-p		MRLCLAHsPPVKSFL	19171932	1	7	1		
type 2 diabetes	increased	Gsk3b	GSK3B	Q9WV60	56637	16|16 B3	46.71	mouse	449111	S9-p		SGRPRTTsFAESCKP	18701453	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
type 2 diabetes	decreased	Eif2b5	eIF2B-epsilon	Q8CHW4	224045	16|16 A3	80.09	mouse	449906	S540-p		ELDSRAGsPQLDDIR	18701453	5	76	9		
Fetal growth restriction	increased; molecular association	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451659	S144-p		NFHLMAPsEEDHSIL	19193607	11	9	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	455532	Y455-p		PPHLKYLyLVVSDSG	19336760	8	0	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	455531	Y453-p		PTPPHLKyLYLVVSD	19336760	6	0	0		
PFCP	deletion of site	Epor	EPOR	P14753	13857	9 A3|9 7.93 cM	55.19	mouse	449885	Y503-p		SEPLHPGyVACS___	19336760	9	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	8506352	105	49	116	39357	
Alzheimer's disease	mutation of site	APP	APP	P05067	351	21q21.3	86.94	human	3173810	K670-sm		TEEISEVkMDAEFRH	1302033	2	0	0		
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	8858002	42	29	23	12885	Guam ALS/parkinsonism-dementia complex
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	19451179	36	13	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	19451179	116	41	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	19451179	70	26	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	19451179	20	26	6		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	19451179	102	48	69	35834; 20194	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	19451179	84	19	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	19451179	73	20	26	49561	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	19451179	105	49	116	39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	19451179	32	6	0		
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	8858002	116	41	90	9632	Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	8858002	32	6	0		Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	8858002	84	19	2		Guam ALS/parkinsonism-dementia complex
Parkinson's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	8858002	86	37	14		Guam ALS/parkinsonism-dementia complex
Parkinson's disease	decreased; increased	HTRA2	HTRA2	O43464	27429	2p13.1	48.84	human	487466	S142-p		VPSPPPAsPRSQYNF	17906618	4	0	1		hyperphosphorylation in Parkinsons disease brains; hypophosphorylation in Parkinson's disease brains carrying C575R and Y431H mutations 
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448471	Y1233-p	Pkinase_Tyr	DMYDKEYySVHNKTG	19595710	45	16	442	3129; 3077; 3126; 4091; 4033; 12468	
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448470	Y1232-p	Pkinase_Tyr	RDMYDKEyYSVHNKT	19595710	47	35	740	3129; 3077; 3126; 4091; 4033; 12468	
ALS	increased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	448866	Y1228-p	Pkinase_Tyr	FGLARDMyDKEYYSV	19595710	6	11	108		
ALS	decreased	Met	Met	P16056	17295	6 A2|6 7.83 cM	153.55	mouse	450188	S983-p		PHLDRLVsARSVSPT	19595710	7	1	0		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	19659459	32	6	0		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	19659459	105	49	116	39357	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	19659459	102	48	69	35834; 20194	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	19659459	84	19	2		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	19659459	20	26	6		
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	19659459	70	26	33	29957	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	19659459	116	41	90	9632	
type 2 diabetes; Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	19659459	42	29	23	12885	
retinitis pigmentosa	mutation of site	PRPF3	PRPF3	O43395	9129	1q21.2	77.53	human	999610	T494-p	PRP3	TEAVQDPtKVEAHVR	17932117	1	0	0		retinitis pigmentosa type 18 (RP18);  T494M mutation
Parkinson's disease	mutation of site	NR4A2	NR4A2	P43354	4929	2q24.1	66.59	human	487428	S125-p		GSVYYKPsSPPTPTT	17890097	1	0	0		patient with S125C mutation
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448055	Y1016-p		DVVDADEyLIPQQGF	19002495	43	6	12	2235	Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448060	Y1197-p		STAENAEyLRVAPQS	19002495	84	56	1028	2244; 4407	Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. 
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447582	S37-p		YLDSGIHsGATTTAP	11181454	70	3	12	4270; 2009; 13537; 9561	
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447488	S45-p		GATTTAPsLSGKGNP	11181454	28	6	0	19807; 70034; 9565; 9564	
colorectal cancer	mutation of site	Ctnnb1	CTNNB1	Q9WU82	84353	8q32	85.45	rat	447583	T41-p		GIHSGATtTAPSLSG	11181454	59	3	0	4270; 13537; 9561; 9565	
depression	mutation of site	Grin2a	NMDAR2A	P35436	14811	16 A1|16 5.28 cM	165.42	mouse	458211	Y1325-p	NMDAR2_C	RLLEGNLyGSLFSVP	19834457	4	2	84		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	454127	S416-p		SNVSSTGsIDMVDSP	9832145	5	11	0	15013	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450220	S185-p		APKTPPSsGEPPKSG	9832145	2	4	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449130	S400-p		VYKSPVVsGDTSPRH	9832145	12	39	70	35834; 20194	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487451	S238-p		TPPKSPSsAKSRLQT	9832145	2	5	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	456456	T414-p		HLSNVSStGSIDMVD	9832145	1	6	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452074	S237-p		RTPPKSPsSAKSRLQ	9832145	2	9	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449104	S356-p	Tubulin-binding	RVQSKIGsLDNITHV	9832145	24	21	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	9832145	36	13	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	9832145	84	19	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	9832145	4	27	26	35834; 20194	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	9832145	20	26	6		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	9832145	102	48	69	35834; 20194	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	9832145	105	49	116	39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	464351	Y197-p		KSGDRSGySSPGSPG	9832145	4	6	34		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	9832145	116	41	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	9832145	86	37	14		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487450	S210-p		PGTPGSRsRTPSLPT	9832145	2	5	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	9832145	8	8	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449132	S409-p		DTSPRHLsNVSSTGS	9832145	13	9	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	9832145	39	33	25		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	9832145	19	13	10		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	456455	S412-p		PRHLSNVsSTGSIDM	9832145	1	7	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	9832145	46	19	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452062	S184-p		PAPKTPPsSGEPPKS	9832145	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	9832145	42	29	23	12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449084	S413-p		RHLSNVSsTGSIDMV	9832145	4	6	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	9832145	70	26	33	29957	
depression	mutation of site	Ppp1r1b	DARPP-32	Q60829	19049	11|11 D	21.78	mouse	448047	T34-p	DARPP-32	MIRRRRPtPAMLFRV	19834457	60	5	44	12438	
lung cancer	increased	CDCA8	Borealin	Q53HL2	55143	1p34.3	31.32	human	482837	T278-p		QICSSIRtHK_____	17483322	1	0	0		
lung cancer	increased	CDCA8	Borealin	Q53HL2	55143	1p34.3	31.32	human	482836	S275-p	Borealin	RLAQICSsIRTHK__	17483322	1	1	0		
ovarian cancer	increased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	11496001	T120-p	Pkinase	IIRLRNKtLTEDEIA	19940129	3	0	0		
ovarian cancer	decreased	STK4	MST1	Q13043	6789	20q13.12	55.63	human	447925	T183-p	Pkinase	DTMAKRNtVIGTPFW	19940129	15	1	5	3681; 49332	
Aarskog-Scott syndrome	mutation of site	Fgd1	FGD1	P52734	14163	X F3|X 68.46 cM	106.36	mouse	3193805	S205-p		LVPRAEAsTSSAAVS	20045932	2	2	0		
colorectal cancer	increased	PXN	PXN iso2	P49023-2	5829	12q24.23	60.97	human	448909	Y88-p	Paxillin	PQSSSPVyGSSAKTS	20133777	4	48	1343		dephosphorylation of PXN Y88 is tumor suppressive
psoriasis	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447496	T46-p	eIF_4EBP	GGTLFSTtPGGTRII	19663871	114	34	91	2855; 3929; 5123; 7547; 9459; 2846; 4923	in lesional, but not in nonlesional, plaque-type psoriatic skin
psoriasis	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447497	T37-p	eIF_4EBP	PPGDYSTtPGGTLFS	19663871	113	42	88	2855; 3929; 5123; 7547; 9459; 2846; 4923	in lesional, but not in nonlesional, plaque-type psoriatic skin
myeloproliferative disorder	increased	Mpl	MPL	Q08351	17480	4 D2.1|4 54.61 cM	69.79	mouse	450267	Y616-p		THIANHSyLPLSYWQ	19996410	7	1	1	12712	constitutive phosphorylation of this site in Mpl W515K/L mutant
Alzheimer's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	19889641	42	5	0	23706	Lewybody disease
pancreatic cancer		RALA	RALA	P11233	5898	7p14.1	23.57	human	483989	S194-p		NGKKKRKsLAKRIRE	19901077	3	0	1		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	12056100	S16-p		KAFESLKsFQQQQQQ	20064390	11	0	0		
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	10206805	S13-p		KLMKAFEsLKSFQQQ	20064390	10	1	0		
osteopenia		Naca	NACA	P70670	17938	10|10 D3	220.50	mouse	454238	S2015-p		PELEEQDsTQTATQQ	19884350	2	1	0		S43A homozygote mice shows a decreased bone volume
colorectal cancer	increased	Pxn	PXN	Q8VI36	19303	5 F|5 56.1 cM	64.48	mouse	448909	Y88-p	Paxillin	PPSPLPVySSSAKNS	20133777	4	48	1343		dephosphorylation of PXN Y88 is tumor suppressive
hepatitis B	increased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447734	S53-p		ISVSRSTsFRGGMGS	20334631	16	12	14		
hepatitis B	increased	KRT18	K18	P05783	3875	12q13.13	48.06	human	447733	S34-p		RPVSSAAsVYAGAGG	20334631	14	26	13		
sickle-cell anaemia	increased	EPB41	EPB41 iso4	P11171-4	2035	1p35.3	66.40	human	463285	Y13-p	FERM_N	SLLDDTVyECVVEKH	20206558	1	5	46		
Parkinson's disease	increased	PRDX2	PRDX2	P32119	7001	19p13.13	21.89	human	487517	T89-p	AhpC-TSA	THLAWINtPRKEGGL	17610816	1	1	0		
ovarian cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448176	T212-p		VIEPLPVtPTRDVAT	19876919	13	26	19		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	19821112	36	13	5		
breast cancer	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	475060	Y74-p	CDI	HKPLEGKyEWQEVEK	17254967	7	0	0		
breast cancer	increased	HSPB1	HSP27	P04792	3315	7q11.23	22.78	human	448402	S78-p		PAYSRALsRQLSSGV	17697330	26	22	30	2405	Only in HER-2/neu positive tumors
type 2 diabetes	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	361	6	1	9209; 9206; 97596; 9234; 9205	
type 2 diabetes	increased	Rps6kb1	p70S6K	P67999	83840	10q26	59.13	rat	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	361	6	1	9209; 9206; 97596; 9234; 9205	
type 2 diabetes	increased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	453434	S1101-p		GCRRRHSsETFSSTP	17709744	9	36	122	2385	
type 2 diabetes	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	453434	S1097-p		GCRRRHSsETFSAPT	17709744	9	36	122	2385	
type 2 diabetes	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	453434	S1100-p		GCRRRHSsETFSAPT	17709744	9	36	122	2385	
type 2 diabetes	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	17709744	361	6	1	9209; 9206; 97596; 9234; 9205	
breast cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17545609	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
infertility	mutation of site	Espl1	separase	P60330	105988	15|15 F3	233.03	mouse	447673	S1121-p		IQSSVNSsPVLKTKP	18232736	10	10	0		Ser1121Ala mutant mice are infertile
ovarian cancer	increased	AKT2	Akt2	P31751	208	19q13.2	55.77	human	448520	S474-p	Pkinase_C	RTHFPQFsYSASIRE	10822383	20	8	55	88106; 9271; 3787; 4060; 5315; 9563; 4070; 15116; 4051; 5102; 4075; 5012; 4071; 8599; 4058; 11962; 2336; 2337; 12694	
Alzheimer's disease	decreased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449083	S422-p		GSIDMVDsPQLATLA	16606369	32	6	0		The tangles associated with Alzheimer's disease are correlated with a loss of phosphorylation at S422 in those cells.  However, phosphorylation of S422 appears to precede the cleavage event and may serve to protect Tau from cleavage.
ataxia-telangiectasia	decreased	ABL1	Abl	P00519	25	9q34.12	122.87	human	450296	S446-p	Pkinase_Tyr	PYPGIDLsQVYELLE	9168116	2	0	0		
Alzheimer's disease	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	18208556	64	0	0		
Alzheimer's disease	increased	Ppp2ca	PPP2CA	P63330	19052	11|11 B1.3	35.61	mouse	448571	Y307-p		VTRRTPDyFL_____	18208556	64	0	0		
Status epilepticus	decreased	Gabrb3	GABRB3	P63080	14402	7 B5|7 33.53 cM	54.17	mouse	450246	S433-p	Neur_chan_memb	THLRRRSsQLKIKIP	18184780	12	0	3		
Status epilepticus	decreased	Gabrb3	GABRB3	P63080	14402	7 B5|7 33.53 cM	54.17	mouse	450245	S432-p	Neur_chan_memb	KTHLRRRsSQLKIKI	18184780	11	0	0		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448081	S518-p		KTVTPASsAKTSPAK	10757975	7	31	17		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	10757975	20	47	84		
Alzheimer's disease	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448083	T509-p		PVCEVSVtPKTVTPA	10757975	11	62	34		
Parkinson's disease	increased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	18371080	19	0	0		
major depressive disorder	decreased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	16959794	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	16959794	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	16959794	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	using DISC1 ser704cys allele
major depressive disorder	decreased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16959794	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	using DISC1 ser704cys allele
major depressive disorder	decreased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	16959794	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	using DISC1 ser704cys allele
neuroblastoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	17234785	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
neuroblastoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	17234785	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
medullary thyroid carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17209045	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	17209045	145	53	67	9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17209045	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17209045	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	in tumors with activated RET (S891A allele)
medullary thyroid carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17209045	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	in tumors with activated RET (S891A allele)
glioblastoma multiforme	increased	AGAP2	CENTG1 iso2	Q99490-2	116986	12q14.1	90.54	human	478561	S279-p		YSSSLPSsPNVGHRE	18487454	1	2	20		
prostate cancer	increased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	15580310	19	0	0		
acute myelogenous leukemia	increased	ACIN1	acinus	Q9UKV3	22985	14q11.2	151.86	human	456759	S1180-p	RSB_motif	GPRSRSRsRDRRRKE	18559500	4	2	0		
prostate cancer	decreased; mutation of site	NKX3-1	NKX3-1	Q99801	4824	8p21.2	26.35	human	3078000	S48-p		RQGGRTSsQRQRDPE	11980664	1	0	0		polymorphism disturbs PKC consensus motif
DSPS	mutation of site	AANAT	AA-NAT iso100	Q16613_VAR_A129T	15	17q25.1	23.37	human	3251801	T129-p	Acetyltransf_1	HVLAVHRtFRQQGRG	12736803	1	0	0		
SLE		SNRNP70	snRNP 70	P08621	6625	19q13.33	51.56	human	2103618	S140-p	RRM_1	HMVYSKRsGKPRGYA	12548559	2	0	1		recognized by antibodies from lupus patients
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	449898	S8-p		MPLNRTLsMSSLPGL	17698598	15	1	0		
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	448237	S641-p	Glycogen_syn	YRYPRPAsVPPSPSL	17698598	31	27	2	47043; 3891	
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	448238	S645-p	Glycogen_syn	RPASVPPsPSLSRHS	17698598	21	31	7		
type 2 diabetes		GYS1	GYS1	P13807	2997	19q13.33	83.79	human	451605	S11-p		NRTLSMSsLPGLEDW	17698598	9	2	1		
Marfan syndrome	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447495	S467-p		SVRCSSMs_______	15731757	35	0	5	18338; 3108; 26945; 11979; 8828; 68550; 56532	
Marfan syndrome	increased	SMAD2	SMAD2	Q15796	4087	18q21.1	52.31	human	447494	S465-p		SPSVRCSsMS_____	15731757	35	0	5	18338; 3108; 26945; 11979; 8828; 68550; 56532	
obesity, hyperphagic	decreased	Pparg	PPAR-gamma	P37238	19016	6 E3|6 53.41 cM	57.60	mouse	448062	S112-p		AIKVEPAsPPYYSEK	18204460	23	5	0		
breast cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447975	S249-p		AVIPINGsPRTPRRG	17599043	13	44	86		
breast cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	449821	T252-p		PINGSPRtPRRGQNR	17599043	15	22	68		
pancreatic carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18519681	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
acute myelogenous leukemia	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	18056483	344	100	3046	6943; 2101	
acute myelogenous leukemia	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447528	T70-p	eIF_4EBP	RNSPVTKtPPRDLPT	18056483	45	56	9	9455; 13396	
acute myelogenous leukemia	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	18056483	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
SLE	decreased	ELF1	Elf-1	P32519	1997	13q14.11	67.50	human	4825111	T231-p	Ets	CPKYIKWtQREKGIF	18714041	1	1	0		
Alzheimer's disease	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	15033922	137	22	277	8566; 9337; 9316; 9331; 5090; 9327; 8452	
Alzheimer's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15033922	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
colorectal cancer		PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447966	Y925-p	Focal_AT	DRSNDKVyENVTGLV	15958584	85	17	427	3284	
colorectal cancer		PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447965	Y861-p		PIGNQHIyQPVGKPD	15958584	68	21	307		
colorectal cancer		SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	15958584	344	100	3046	6943; 2101	
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	448106	S419-p		GGRSRSGsIVELIAG	18772195	10	27	21		phosphorylation decreased in HD; experimental phosphorylation restores defects in function
infertility	mutation of site	BMP15	BMP15	O95972	9210	Xp11.22	45.06	human	9379003	Y235-p		DIAFLLLyFNDTHKS	19553676	1	0	0		Y235C mutation causes hypergonadotropic ovarian failure
astrocytoma	decreased	AQP4	AQP4	P55087	361	18q11.2	34.83	human	467301	S180-p	MIP	TIFASCDsKRTDVTG	19761816	4	0	0		
ovarian cancer	increased	PAK2	PAK2	Q13177	5062	3q29	58.04	human	448298	S20-p		APPVRMSsTIFSTGG	19876919	7	11	100	2607	
ovarian cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448177	T423-p	Pkinase	PEQSKRStMVGTPYW	19876919	32	3	11	2601	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	19821112	86	37	14		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	19821112	39	33	25		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	19821112	46	19	42	77348	
acute myelogenous leukemia	increased	CSF2RB	CSF2RB	P32927	1439	22q12.3	97.34	human	448463	S601-p		LGPPHSRsLPDILGQ	19805619	6	1	0		
ovarian cancer	increased	JUND	JunD	P17535	3727	19p13.11	35.17	human	456168	S100-p	Jun	LGLLKLAsPELERLI	17001009	5	62	12	9164	
ovarian cancer	increased	PLEKHA6	PLEKHA6	Q9Y2H5	22874	1q32.1	117.13	human	11452200	S455-p		SLQPRSHsVPRSPSQ	17001009	0	5	1		
ovarian cancer	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	17001009	67	3	2	4270; 2009; 13537; 9561	
ovarian cancer	increased	SYNM	DMN	O15061	23336	15q26.3	172.77	human	3207309	S429-p		QTNVRTFsPTYGLLR	17001009	1	22	3		
ovarian cancer	increased	TNS3	tensin 3	Q68CZ2	64759	7p12.3	155.27	human	4726261	S1441-p	PTB	VSKVMIGsPKKV___	17001009	1	18	0		
ovarian cancer	increased	IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	453065	S1100-p		PEAARVAsPTSGVKR	17001009	2	42	0		
ovarian cancer	increased	RIPOR1	FAM65A	Q6ZS17	79567	16q22.1	132.31	human	10424020	S453-p		APYSRTLsHISEASV	17001009	0	1	1		
ovarian cancer	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447943	S73-p	Jun	VGLLKLAsPELERLI	17001009	73	64	16	8752; 9164; 3270; 12714	
melanoma skin cancer	increased	USP10	USP10	Q14694	9100	16q24.1	87.13	human	480435	S547-p	UCH	LNLKKLLsPSNEKLT	17001009	0	21	1		
melanoma skin cancer	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447943	S73-p	Jun	VGLLKLAsPELERLI	17001009	73	64	16	8752; 9164; 3270; 12714	
melanoma skin cancer	increased	RIPOR1	FAM65A	Q6ZS17	79567	16q22.1	132.31	human	10424020	S453-p		APYSRTLsHISEASV	17001009	0	1	1		
melanoma skin cancer	increased	RPS17	RPS17	P08708	6218	15q25.2	15.55	human	4710792	S115-p	Ribosomal_S17e	LLDFGSLsNLQVTQP	17001009	0	10	11		
melanoma skin cancer	increased	JUND	JunD	P17535	3727	19p13.11	35.17	human	456168	S100-p	Jun	LGLLKLAsPELERLI	17001009	5	62	12	9164	
melanoma skin cancer	increased	TNS3	tensin 3	Q68CZ2	64759	7p12.3	155.27	human	4726261	S1441-p	PTB	VSKVMIGsPKKV___	17001009	1	18	0		
melanoma skin cancer	increased	TAF13	TAF13	Q15543	6884	1p13.3	14.29	human	487235	S33-p	TFIID-18kDa	GKRKRLFsKELRCMM	17001009	0	3	10		
melanoma skin cancer	increased	SYNM	DMN	O15061	23336	15q26.3	172.77	human	3207309	S429-p		QTNVRTFsPTYGLLR	17001009	1	22	3		
melanoma skin cancer	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447487	S33-p		QQQSYLDsGIHSGAT	17001009	67	3	2	4270; 2009; 13537; 9561	
melanoma skin cancer	increased	IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	453065	S1100-p		PEAARVAsPTSGVKR	17001009	2	42	0		
melanoma skin cancer	increased	BCAR3	BCAR3	O75815	8412	1p22.1	92.57	human	7989842	T130-p		ERHIMDRtPEKLKKE	17001009	0	5	15		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	19940281	82	2	0	2511	High S118 ER-alpha phosphorylation is found in some breast cancer tumors. 
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	6211807	Y1499-p		ERTKLGDyANLKQFY	20206558	1	1	0		
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	13421404	Y548-p	Spectrin	KLIGDDHyDSENIKA	20206558	1	1	0		
sickle-cell anaemia	increased	SPTA1	SPTA1	P02549	6708	1q23.1	280.01	human	13421405	Y422-p	Spectrin	HKHEIDSyDDRFQSA	20206558	1	1	0		
ovarian cancer	increased	ERBB3	HER3	P21860	2065	12q13.2	148.10	human	449858	Y1289-p		CPASEQGyEEMRAFQ	20227043	19	10	125	2842; 4791	
ovarian cancer	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20153512	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	phosphorylated in a majority of tumor specimens
prostate cancer	increased	ARHGEF2	ARHGEF2 iso2	Q92974-2	9181	1q22	111.47	human	451365	S885-p		PVDPRRRsLPAGDAL	20406887	9	46	145	14143	
pancreatic carcinoma	increased	ENO1	ENO1	P06733	2023	1p36.23	47.17	human	7104866	S419-p	Enolase_C	RIEEELGsKAKFAGR	20455595	2	31	0		presence of autoantibodies directed against phosphorylated S419 in patients with pancreatic cancer
acute lymphocytic leukemia; acute myelogenous leukemia; chronic myelogenous leukemia	increased	STAT5A	STAT5A	P42229	6776	17q21.2	90.65	human	448750	S780-p		DSLDSRLsPPAGLFT	20508164	9	24	0		phosphorylation of this site was not detected in bone marrow samples obtained from healthy donors
adrenocortical carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	20484036	129	14	106	2971; 5536; 2976	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
adrenocortical carcinoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448095	S244-p		LRASTSKsESSQK__	20484036	66	31	561	13020; 5044; 9468; 14236; 5018; 2215; 5364	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
adrenocortical carcinoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448094	S240-p		RLSSLRAsTSKSESS	20484036	66	65	847	13020; 5044; 9468; 14236; 5018; 2215; 5364	mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis
glioblastoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	20455003	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	Y705 phosphorylation is a prognostic factor for survival (patients with higher levels had shorter overall survival than those with lower levels)
tuberous sclerosis	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448095	S244-p		LRASTSKsESSQK__	17671177	66	31	561	13020; 5044; 9468; 14236; 5018; 2215; 5364	
tuberous sclerosis	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17671177	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
tuberous sclerosis	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17671177	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
tuberous sclerosis	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17671177	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
tuberous sclerosis	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448094	S240-p		RLSSLRAsTSKSESS	17671177	66	65	847	13020; 5044; 9468; 14236; 5018; 2215; 5364	
tuberous sclerosis	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17671177	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
colorectal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	460647	Y380-p	Peptidase_C14	TDSEEQPyLEMDLSS	16619028	8	3	35		
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	456511	T655-p	Pkinase_C	TRAAPALtPPDRLVL	15964845	2	14	2		missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	451041	T514-p	Pkinase	FPGTTTRtFCGTPDY	15964845	4	44	45	9379; 2060; 38938	missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
spinocerebellar ataxia type 14	decreased	PRKCG	PKCG	P05129	5582	19q13.42	78.45	human	456512	T674-p	Pkinase_C	QADFQGFtYVNPDFV	15964845	3	3	1		missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.
pulmonary emphysema	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	14764579	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
pulmonary emphysema	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	14764579	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
pulmonary emphysema	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	14764579	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
pulmonary emphysema	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	14764579	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
cancer, squamous cell carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	14603053	278	31	474	8556; 3283	FAK pY397 was more nuclear; however, little correlation between pY397 and tumor differentiation
colorectal cancer	decreased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447888	Y407-p		IIDEEDTyTMPSTRD	12871985	27	13	139		pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.
colorectal cancer	decreased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	12871985	278	31	474	8556; 3283	pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448233	Y216-p	SH2	KLDSGGFyITSRTQF	12753909	7	3	21		HER2(+) breast cancer.  Strong pY216, modest  pY419.
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	12753909	344	100	3046	6943; 2101	HER2(+) breast cancer.  Strong pY216, modest  pY419.
spinocerebellar ataxia type 1	increased	ATXN1	ataxin-1	P54253	6310	6p22.3	86.92	human	449110	S775-p		ATRKRRWsAPESRKL	12741986	15	25	3		
non-small cell large cell lung carcinoma; non-small cell squamous cell lung carcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	Pkinase_Tyr	LGAEEKEyHAEGGKV	16505275	77	19	171	2231; 6963	
ARVC	mutation of site	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	2535900	G1885-p		GEEEAKGgKRPKEGL	18326664	1	0	0		
hepatocellular carcinoma	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	Pkinase_Tyr	LGAEEKEyHAEGGKV	16936701	77	19	171	2231; 6963	
acute myelogenous leukemia	mutation of site	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448190	Y591-p		SSDNEYFyVDFREYE	17105820	14	0	0	3474; 3466; 3461; 3464	duplication of site
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	11034902	116	41	90	9632	Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. 
breast cancer	increased	Erbb2	HER2	P06494	24337	10q31	138.83	rat	447614	Y1250-p		PTAENPEyLGLDVPV	9461599	52	15	200	2244; 2247	
kidney cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	12649200	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
breast cancer	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	17967179	344	100	3046	6943; 2101	in selected cell lines
breast cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	17967179	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	in selected cell lines
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448061	Y869-p	Pkinase_Tyr	LGAEEKEyHAEGGKV	17653080	77	19	171	2231; 6963	
esophageal carcinoma	mutation of site	FBXO4	FBXO4	Q9UKT5	26272	5p13.1	44.14	human	453026	S12-p		EPRSGTNsPPPPFSD	18598945	2	36	0		
Burkitt's lymphoma	mutation of site	MYC	Myc	P01106	4609	8q24.21	48.80	human	448496	T58-p	Myc_N	KKFELLPtPPLSPSR	10713166	56	37	30		
Emery-Dreifuss muscular dystrophy	mutation of site	LMNA	lamin A/C	P02545	4000	1q22	74.14	human	478681	S404-p		RSRGRASsHSSQTQG	18808171	4	46	106		
colorectal carcinoma	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	12234980	211	12	1	3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475	
intraocular melanoma	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	448717	S811-p	Rb_C	IYISPLKsPYKISEG	10969768	62	38	80	8974; 8957; 8516; 4277; 9308; 11917	
intraocular melanoma	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	10969768	63	43	112	8974; 8957; 8516; 4277; 9308; 11917	
acute myelogenous leukemia	duplication	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448190	Y591-p		SSDNEYFyVDFREYE	9305596	14	0	0	3474; 3466; 3461; 3464	
lung cancer		Stat1	STAT1	P42225	20846	1 C1.1|1 26.81 cM	87.20	mouse	447754	Y701-p		DDPKRTGyIKTELIS	18941537	138	6	64	25809; 8009; 8062; 9174; 9167; 5375; 8183; 7649	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447933	T205-p		SSPGSPGtPGSRSRT	18725412	73	20	26	49561	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	18725412	102	48	69	35834; 20194	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	18725412	116	41	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	18725412	70	26	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447929	S214-p		GSRSRTPsLPTPPTR	18725412	46	19	42	77348	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	18725412	36	13	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	18725412	105	49	116	39357	
acute myelogenous leukemia	duplication	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	448643	Y599-p		VDFREYEyDLKWEFP	9305596	7	0	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	11034902	102	48	69	35834; 20194	Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. 
ovarian cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447529	S20-p	P53_TAD	PLSQETFsDLWKLLP	20009884	118	1	0	9287	In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.
ovarian cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447535	S392-p		FKTEGPDsD______	20009884	95	14	0	9281	In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.
cancer, squamous cell carcinoma	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	19934324	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
cancer, squamous cell carcinoma	increased	Mapk1	ERK2	P63085	26413	16 A3|16 10.53 cM	41.28	mouse	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	19934324	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
cancer, squamous cell carcinoma	increased	Mapk3	ERK1	Q63844	26417	7 F3|7 69.25 cM	43.07	mouse	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	19934324	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
cancer, squamous cell carcinoma	increased	Pdpk1	PDK1	Q9Z2A0	18607	17|17 A3.3	63.76	mouse	447693	S244-p	Pkinase	SKQARANsFVGTAQY	19934324	56	92	264	3438; 3061	
cancer, squamous cell carcinoma	increased	Stat3	STAT3	P42227	20848	11 D|11 63.82 cM	88.05	mouse	448192	Y705-p		DPGSAAPyLKTKFIC	19934324	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
cancer, squamous cell carcinoma	increased	Mapk3	ERK1	Q63844	26417	7 F3|7 69.25 cM	43.07	mouse	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	19934324	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
cancer, squamous cell carcinoma	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	Pkinase_Tyr	RLIEDNEyTARQGAK	19934324	20	92	3048	6943; 2101	
breast cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455677	S28-p	Histone	ATKAARKsAPATGGV	19956839	45	17	0	9713	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
breast cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447498	S2481-p		TVPESIHsFIGDGLV	19956839	51	27	1	2974	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
breast cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	19956839	211	12	1	3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475	mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	487463	Y394-p		DHGAEIVyKSPVVSG	20110615	2	14	33		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	20110615	116	41	90	9632	
hepatocellular carcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	20224721	137	4	0	4887; 3036; 5733; 3031; 4886; 4025; 3033; 13346	fibrolamellar hepatocellular carcinoma.  high levels of phosphorylation in 88% of fibrolamellar hepatocellular carcinoma sample, 10% of normal liver samples.
LVR; MI	decreased	Tnnt2	TNNT2	P50753	24837	13q13	35.73	rat	451755	S209-p	Troponin	KAQTERKsGKRQTER	20418543	9	0	0		
LVR; MI	decreased	TNNT2	TNNT2	P45379	7139	1q32.1	35.92	human	451755	S208-p	Troponin	QAQTERKsGKRQTER	20418543	9	0	0		
Parkinson's disease; Alzheimer's disease	increased	Apex1	APE1	P28352	11792	14 C1|14 26.3 cM	35.49	mouse	14645304	T232-p	Exo_endo_phos	NKKNAGFtPQERQGF	20473298	2	0	0		
colorectal cancer	increased	TNIK	TNIK	Q9UKE5	23043	3q26.2-q26.31	154.94	human	451976	S764-p		RTRVRANsKSEGSPV	20530691	1	22	23		
Alzheimer's disease	decreased	Grin2b	NMDAR2B	Q01097	14812	6 G1|6 66.38 cM	165.96	mouse	448167	Y1472-p	NMDAR2_C	GSSNGHVyEKLSSIE	20427654	27	1	104	4208	result of increased levels and activity of STEP phosphatase in aged Tg2576 mice   
prostate cancer	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	450946	Y284-p	Pkinase_Tyr	LPQNDDHyVMQEHRK	20623637	6	27	235	3138	correlates positively with disease progression and negatively with survival of patients
Parkinson's disease	decreased	Lrrk2	LRRK2	Q5S006	66725	15|15 E3	284.73	mouse	4725893	S910-p		LVKRKSNsISVGEVY	20642453	15	15	0		phosphorylation of this site and interaction with 14-3-3 were abolished in the LRRK2[R1441C] knockin mice 
Parkinson's disease	decreased	Lrrk2	LRRK2	Q5S006	66725	15|15 E3	284.73	mouse	4725898	S935-p		NAQRHSNsLGPVFDH	20642453	21	15	2		phosphorylation of this site and interaction with 14-3-3 were abolished in the LRRK2[R1441C] knockin mice 
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448044	S620-p		AKSPVPKsPVEEKGK	20624930	3	28	24		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451036	S672-p		GKSPVSKsPVEEKAK	20624930	0	10	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451038	S685-p		AKSPVPKsPVEEAKS	20624930	0	16	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	476043	S788-p		GGSEEEGsDKGAKGS	20624930	0	4	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451033	S646-p		GKSPVPKsPVEEKGK	20624930	0	14	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451045	S837-p		VTNGLDLsPADEKKG	20624930	1	19	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	476042	S783-p		KAGGEGGsEEEGSDK	20624930	0	11	3		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451035	S667-p		PVEEKGKsPVSKSPV	20624930	0	10	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448045	S736-p		PEKKKAEsPVKEEAV	20624930	4	23	1		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451034	S659-p		GKSPVPKsPVEEKGK	20624930	0	14	2		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	456826	S680-p		PVEEKAKsPVPKSPV	20624930	0	13	0		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451836	S615-p		EKPEKAKsPVPKSPV	20624930	4	19	19		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451032	S641-p		PVEEKGKsPVPKSPV	20624930	0	14	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456829	S801-p		PVKEEVKsPEKAKSP	20624930	0	11	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481094	S716-p	DUF1388	KSPEKAKsPVKEEAK	20624930	0	8	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481078	S648-p	DUF1388	PTKEEAKsPEKAKSP	20624930	0	8	5		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	483057	S744-p	DUF1388	KTPEKAKsPVKEEAK	20624930	0	8	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481076	S640-p	DUF1388	KSPEKAKsPTKEEAK	20624930	0	8	4		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456921	S546-p	DUF1388; DUF1388	KSPAEVKsPEKAKSP	20624930	0	13	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456929	S710-p	DUF1388	PVKEEAKsPEKAKSP	20624930	0	15	0		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481063	S580-p	DUF1388	KSPAEVKsPEKAKSP	20624930	0	15	4		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	456928	S702-p	DUF1388	KSPEKAKsPVKEEAK	20624930	0	15	9		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	481070	S620-p	DUF1388	KSPAEAKsPVKEEAK	20624930	0	12	6		
breast cancer	increased	ITGB4	ITGB4 iso2	P16144-2	3691	17q25.1	195.01	human	456323	Y1494-p	fn3	LQGYSVEyQLLNGGE	20855525	5	0	1		
breast cancer	increased	FYN	Fyn	P06241	2534	6q21	60.76	human	447882	Y420-p	Pkinase_Tyr	RLIEDNEyTARQGAK	20855525	20	92	3048	6943; 2101	
chronic myelogenous leukemia	deletion of site	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448506	Y536-p		QKGQESEyGNITYPP	20858858	16	24	637		
chronic myelogenous leukemia	deletion of site	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448912	Y564-p		SKHKEEVyENVHSKS	20858858	10	18	776	8849	
glioblastoma multiforme	increased	EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	1244153	S897-p		RVSIRLPsTSGSEGV	19573808	4	32	171	6347	high levels in grade IV astrocytomas (GBM)
ovarian epithelial carcinoma	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	21276607	129	14	106	2971; 5536; 2976	
ovarian epithelial carcinoma	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447497	T37-p	eIF_4EBP	PPGDYSTtPGGTLFS	21276607	113	42	88	2855; 3929; 5123; 7547; 9459; 2846; 4923	
ovarian epithelial carcinoma	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	21276607	361	6	1	9209; 9206; 97596; 9234; 9205	
ovarian epithelial carcinoma	increased	EIF4EBP1	4E-BP1	Q13541	1978	8p11.23	12.58	human	447496	T46-p	eIF_4EBP	GGTLFSTtPGGTRII	21276607	114	34	91	2855; 3929; 5123; 7547; 9459; 2846; 4923	
diabetes mellitus	increased	Ubtf	UBF	P25976	21429	11|11 D	89.51	mouse	450170	S389-p		INKKQTTsPASKKPS	20943765	4	3	1		
colonic inflamation	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20580720	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	chronic ulcerative colitis (CUC), ulcerative colitis associated dysplasia (UCD), colitis-associated cancer (CAC)
colonic inflamation	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	472273	S552-p		QDTQRRTsMGGTQQQ	20580720	15	59	9	9566; 5651	chronic ulcerative colitis (CUC), ulcerative colitis associated dysplasia (UCD), colitis-associated cancer (CAC)
diabetes mellitus	increased	Ubtf	UBF	P25977	25574	10q32.1	89.44	rat	450170	S389-p		INKKQTTsPASKKPS	20943765	4	3	1		
diabetes mellitus	increased	Rps6kb1	p70S6K	P67999	83840	10q26	59.13	rat	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	20943765	361	6	1	9209; 9206; 97596; 9234; 9205	
SLE	decreased	SP1	SP1	P08047	6667	12q13.13	80.69	human	452233	S59-p		GGQESQPsPLALLAA	21097497	5	16	0		
B cell lymphoma	mutation of site	RAG2	RAG2	P55895	5897	11p12	59.24	human	455560	T490-p	RAG2_PHD	EIARALHtPQRVLPL	21349429	3	0	0		
scleroderma	increased	FLI1	FLI1	Q01543	2313	11q24.3	50.98	human	6406002	T312-p	Ets	TNGEFKMtDPDEVAR	21321929	6	0	0		
atrial fibrillation	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	22158709	43	6	5		inhibition of RYR2-S2814 phosphorylation prevents AF in FKBP12.6-/- mice
hepatocellular carcinoma	increased	FOXA2	FOXA2	Q9Y261	3170	20p11.21	48.31	human	22825101	S111-p	Forkhead_N	PHLSPSLsPLGGQAA	22196886	1	1	0		
hepatocellular carcinoma	increased	FOXA2	FOXA2	Q9Y261	3170	20p11.21	48.31	human	22825100	S107-p	Forkhead_N	AGMGPHLsPSLSPLG	22196886	1	1	0		
chronic myelogenous leukemia	increased	BCR	Bcr	P11274	613	22q11.23	142.82	human	447792	Y177-p		ADAEKPFyVNVEFHH	12124177	14	30	1018	3901	
breast cancer	increased	STK3	MST2	Q13188	6788	8q22.2	56.30	human	12615900	T117-p	Pkinase	IIRLRNKtLIEDEIA	20231902	2	0	1		
acute lymphocytic leukemia; acute myelogenous leukemia; B cell lymphoma	increased	STAT5B	STAT5B	P51692	6777	17q21.2	89.87	human	483615	S193-p	STAT_alpha	FGPLAQLsPQERLSR	22442148	2	18	1		constitutive phosphorylation of this site was observed
glioblastoma	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	471406	Y333-p		NIMRTYTyEKLLWTT	22056988	2	2	0		
hepatocellular carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	22153071	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
prostate cancer	decreased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	6406005	T120-p		QFDAAHPtNVQRLAE	22511927	4	0	0		
ataxia-telangiectasia	decreased	TP53BP1	53BP1	Q12888	7158	15q15.3	213.57	human	450163	S25-p		PCLIIEDsQPESQVL	19876065	3	0	0	2674	
FTLD	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	449619	S13-p	Filament_head	ITSAARRsYVSSGEM	20886841	10	3	0		
FTLD	decreased	MAP1A	MAP1A	P78559	4130	15q15.3	305.49	human	470449	S612-p		SKDRGLDsGAETEEE	20886841	0	25	31		
Huntington's disease	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447536	S46-p		AMDDLMLsPDDIEQW	22011578	99	3	0	2521	
Alzheimer's disease	increased	MAP2	MAP2	P11137	4133	2q34	199.53	human	13256105	S1702-p	Tubulin-binding	VTKKIDLsHVTSKCG	21828286	0	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	21828286	86	37	14		
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	454141	S1396-p		SPIEKVLsPLRSPPL	21828286	0	57	16		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	452062	S184-p		PAPKTPPsSGEPPKS	21828286	3	4	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	21828286	116	41	90	9632	
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	448045	S736-p		PEKKKAEsPVKEEAV	21828286	4	23	1		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449080	S235-p		VVRTPPKsPSSAKSR	21828286	39	33	25		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	21828286	42	29	23	12885	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	21828286	84	19	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449078	T217-p		SRTPSLPtPPTREPK	21828286	20	26	6		
Alzheimer's disease	increased	MAP2	MAP2	P11137	4133	2q34	199.53	human	7532319	S1706-p	Tubulin-binding	IDLSHVTsKCGSLKN	21828286	0	3	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450220	S185-p		APKTPPSsGEPPKSG	21828286	2	4	1		
Alzheimer's disease	increased	NEFH	NFH	P12036	4744	22q12.2	112.48	human	25322100	S948-p		DAKAKEPsKPAEKKE	21828286	0	1	1		
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	456408	S1779-p		SLEGEKLsPKSDISP	21828286	0	66	53		
Alzheimer's disease	increased	MAP1B	MAP1B	P46821	4131	5q13.2	270.63	human	454142	S1400-p		KVLSPLRsPPLIGSE	21828286	0	65	24		
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	451038	S685-p		AKSPVPKsPVEEAKS	21828286	0	16	3		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	21828286	36	13	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449131	T403-p		SPVVSGDtSPRHLSN	21828286	4	27	26	35834; 20194	
Alzheimer's disease	increased	NEFM	NFM	P07197	4741	8p21.2	102.47	human	10273932	S33-p	Filament_head	RVSGSPSsGFRSQSW	21828286	0	1	0		
breast cancer	increased	PIN1	PIN1	Q13526	5300	19p13.2	18.24	human	25519816	S138-p	Rotamase	QKPFEDAsFALRTGE	22566623	1	2	0		
Parkinson's disease	decreased	Htra2	HTRA2	Q9JIY5	64704	6 C3|6 35.94 cM	49.35	mouse	487467	S400-p	PDZ_2	IHKVILGsPAHRAGL	21701498	2	0	0		In a murine model G399S mutation had decreased S400 phosphorylation. 
ventricular tachycardia	decreased	KCNH2	Kv11.1	Q12809	3757	7q36.1	126.65	human	3893409	S890-p		RQRKRKLsFRRRTDK	22653970	4	1	3		phosphorylation of this site is decreased by T887H nsSNP  mutation in Kv11.1
Parkinson's disease	increased	Sh3glb1	endophilin B1	Q9JK48	54673	3|3 H2	40.86	mouse	26318403	T145-p	BAR	TSALNFLtPLRNFIE	21499257	2	0	0		in Parkinson's disease model, A53T mutant of ?-synuclein
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	22344688	42	5	0	23706	PD patients had higher S129 phosphorylation levels compared to healthy controls. Patients with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) patient, had lower S129 phosphorylation than PD patients or healthy controls. There was a weak correlation with P-S129 levels and severity of the PD.
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	450690	S42-p		AKKKSKIsASRKLQL	22972900	22	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448101	S118-p	Oest_recep	LHPPPQLsPFLQPHG	16168121	82	2	0	2511	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	16168121	38	5	0	42101; 64508	
IPF	increased	CTNNB1	CTNNB1	P35222	1499	3p22.1	85.50	human	447585	Y654-p		RNEGVATyAAAVLFR	19104148	19	2	20		accumulation of pY654??-catenin in myofibroblasts
IPF	increased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447585	Y654-p		RNEGVATyAAAVLFR	19104148	19	2	20		accumulation of pY654??-catenin in myofibroblasts
colorectal cancer	decreased	RORA	RORA	P35398	6095	15q22.2	58.97	human	12613703	S35-p		ETPLNQEsARKSEPP	20122401	1	1	0		
Wilm's tumor	increased	STAT1	STAT1	P42224	6772	2q32.2	87.33	human	447753	S727-p	STAT1_TAZ2bind	TDNLLPMsPEEFDEV	16799645	84	30	90	8826; 9177	
obesity, hyperphagic	mutation of site	NTRK2	TrkB	Q16620	4915	9q21.33	92.00	human	448811	Y706-p	Pkinase_Tyr	RDVYSTDyYRVGGHT	15494731	11	0	49	4621	hyperphagic, early-onset obesity
acute myelogenous leukemia	mutation of site	FLT3	FLT3	P36888	2322	13q12.2	112.90	human	454872	Y842-p	Pkinase_Tyr	DIMSDSNyVVRGNAR	15345593	5	2	76	4577	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447932	T181-p		KTPPAPKtPPSSGEP	12614922	42	29	23	12885	
RIDDLE syndrome	increased	NBN	NBS1	O60934	4683	8q21.3	84.96	human	448605	S343-p		TTPGPSLsQGVSVDE	17940005	41	19	69	3001	in irradiated fibroblasts 
RIDDLE syndrome	increased	SMC1A	Smc1	Q14683	8243	Xp11.22	143.23	human	448698	S966-p	SMC_N	GEDSVSGsQRISSIY	17940005	19	14	67		in irradiated fibroblasts 
RIDDLE syndrome	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	17940005	166	22	4	13050; 4526; 5883	in irradiated fibroblasts 
RIDDLE syndrome	increased	TP53BP1	53BP1	Q12888	7158	15q15.3	213.57	human	458312	S1778-p		FNKQYTEsQLRAGAG	17940005	3	0	1	2675	in irradiated fibroblasts 
RIDDLE syndrome	decreased	CHEK1	Chk1	O14757	1111	11q24.2	54.43	human	447834	S345-p		LVQGISFsQPTCPDH	17940005	140	2	12	2341; 12268; 2348	in irradiated fibroblasts
diabetes mellitus	decreased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	447884	S1176-p		TSRIRTQsFSLQERQ	16085713	157	15	7	9571; 9570	
diabetes mellitus	increased	Nos3	eNOS	Q62600	24600	4q11	133.29	rat	5227904	S1176-gl		TSRIRTQsFSLQERQ	16085713	2	0	0		
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451658	S126-p		GSPESPEsTEITEEE	20143870	11	8	0		
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	451660	S194-p	Thyroglobulin_1	LAKAQETsGEEISKF	20143870	11	12	0		
Fetal growth restriction	increased	IGFBP1	IGFBP1	P08833	3484	7p12.3	27.90	human	4668105	S123-p		AEAGSPEsPESTEIT	20143870	5	7	0		
Status epilepticus	increased	Slc12a5	KCC2	Q91V14	57138	2|2 H3	126.27	mouse	3087801	Y1109-p	SLC12	NRNGDENyMEFLEVL	20600929	3	0	0		phosphorylation of this site enhances lysozomal degradation of SLC12A5 (aka KCC2)
Status epilepticus	increased	Slc12a5	KCC2	Q91V14	57138	2|2 H3	126.27	mouse	14932400	Y926-p	SLC12	SDISAYTyEKTLVME	20600929	1	0	0		phosphorylation of this site enhances lysozomal degradation of SLC12A5 (aka KCC2)
Alzheimer's disease	increased	APP	APP iso4	P05067-4	351	21q21.3	78.66	human	448523	T668-p	APP_amyloid	VEVDAAVtPEERHLS	16705182	36	5	3	6986; 3823	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447933	T516-p		SSPGSPGtPGSRSRT	16705182	73	20	26	49561	
Alzheimer's disease	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	16705182	105	49	116	39357	
rhabdomyosarcoma	mutation of site	KRT8	K8	P05787	3856	12q13.13	53.70	human	3081700	S291-p	Filament	IKYEELQsLAGKHGD	11850543	1	8	5		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447930	S262-p	Tubulin-binding	NVKSKIGsTENLKHQ	15652175	84	19	2		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	450139	S320-p	Tubulin-binding	VDLSKVTsKCGSLGN	15652175	3	0	0		
colorectal cancer		KRT8	K8	P05787	3856	12q13.13	53.70	human	448539	S74-p	Keratin_2_head	TVNQSLLsPLVLEVD	19115206	26	8	9		
colorectal cancer		KRT8	K8	P05787	3856	12q13.13	53.70	human	448540	S432-p		SAYGGLTsPGLSYSL	19115206	26	8	23		
bladder cancer	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	18939995	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
type 2 diabetes	increased	ATP5B	ATP5B	P06576	506	12q13.3	56.56	human	12173904	T213-p	ATP-synt_ab	GGAGVGKtVLIMELI	20012595	0	5	1		22% increase in patients with type II diabetes; 37% increase in obese non-diabetic patients
type 2 diabetes	increased	ATP5B	ATP5B	P06576	506	12q13.3	56.56	human	12173903	Y361-p	ATP-synt_ab	ITSVQAIyVPADDLT	20012595	0	1	13		32% increase in obese non-diabetic patients and patients with type II diabetes
Alzheimer's disease; ALS	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	19046355	8	8	0		T175 phosphorylation induced increased fibril formation in ALS patient samples with cognitive impairment.
cancer, squamous cell carcinoma	increased	FSCN1	fascin	Q16658	6624	7p22.1	54.53	human	450888	S39-p	Fascin	KVNASASsLKKKQIW	20713986	11	12	0		
ventricular tachycardia	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	21098440	43	6	5		
hypertrophic cardiomyopathy	increased	Prkaa1	AMPKA1	P54645	65248	2q16	63.97	rat	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20497424	207	14	33	5256; 2535; 4188; 50081; 2531	
hypertrophic cardiomyopathy	increased	Prkaa1	AMPKA1	Q5EG47	105787	15|15 A1	63.93	mouse	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20497424	207	14	33	5256; 2535; 4188; 50081; 2531	
lung cancer	decreased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	448847	S127-p		PQHVRAHsSPASLQL	21060948	76	29	180	13008; 29495; 4911; 57706	
type 2 diabetes; diabetes mellitus	increased	Mapt	Tau	P19332	29477	10q32.1	78.56	rat	447928	S513-p		SGYSSPGsPGTPGSR	20398714	105	49	116	39357	
hepatocellular carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	20180147	278	31	474	8556; 3283	Phosphorylated Y379 is overexpressed in hepaocellular carcinoma, and correlated with tumor stage, vascular invasion, and intrahepatic  metastasis, 
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448424	S24-p	Troponin-I_N	APIRRRSsNYRAYAT	22972900	51	7	16	4004	similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707828	S5-p	Troponin-I_N	___MADGsSDAAREP	22972900	0	3	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	448423	S23-p	Troponin-I_N	PAPIRRRsSNYRAYA	22972900	55	7	11	4004	similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707836	S6-p	Troponin-I_N	__MADGSsDAAREPR	22972900	0	4	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	decreased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	3545720	Y26-p	Troponin-I_N	IRRRSSNyRAYATEP	22972900	1	2	7		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	2885400	T78-p	Troponin	EKGRALStRCQPLEL	22972900	0	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
prostate cancer	increased	CREB1	CREB	P16220	1385	2q33.3	36.69	human	450092	S129-p	pKID	QKRREILsRRPSYRK	12900420	10	0	2		high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 
prostate cancer	increased	CREB1	CREB	P16220	1385	2q33.3	36.69	human	448228	S133-p	pKID	EILSRRPsYRKILND	12900420	245	4	61	9187; 4095; 9196; 9198; 14228; 14001	high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer 
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15883264	86	37	14		
prostate cancer	increased	AR	AR	P10275	367	Xq12	99.19	human	448714	S83-p	Androgen_recep	QQQQQETsPRQQQQQ	21799006	14	1	0		xenografts 
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	451839	S77-p	Troponin	GEKGRALsTRCQPLE	22972900	2	2	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	450691	S44-p		KKSKISAsRKLQLKT	22972900	22	3	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	26572404	T181-p		KQVKKEDtEKENREV	22972900	0	1	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	3146609	S166-p	Troponin	LGARAKEsLDLRAHL	22972900	1	3	0		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	451483	T143-p	Troponin	RGKFKRPtLRRVRIS	22972900	27	2	1		similar effect has been observed in ISHD (failing ischemic hearts)
DCM	increased	TNNI3	TNNI3	P19429	7137	19q13.42	24.01	human	4707844	S199-p		RKNIDALsGMEGRKK	22972900	2	5	0		similar effect has been observed in ISHD (failing ischemic hearts)
urethral cancer; brain cancer; colorectal cancer	increased	PHF20	PHF20	Q9BVI0	51230	20q11.22-q11.23	115.39	human	23303200	S291-p		ELRRRKIsKGCEVPL	22975685	2	0	0		
urethral cancer; brain cancer; colorectal cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	22975685	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
HIV/AIDS	increased	Rb1	Rb	P33568	24708	15q11	105.03	rat	447979	S787-p	Rb_C	SPYKFSSsPLRIPGG	21504794	44	16	94	9301	
lung cancer	increased	SP1	SP1	P08047	6667	12q13.13	80.69	human	448227	T739-p		SEGSGTAtPSALITT	22266860	14	1	0		
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	448803	S853-p		IAEPMRRsVSEAALA	18398140	30	10	2	4139	
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	450194	S950-p	Abhydrolase_3	EGFHPRRsSQGATQM	18398140	7	4	4		
obesity, hyperphagic	decreased	LIPE	HSL	Q05469	3991	19q13.2	116.60	human	448804	S855-p		EPMRRSVsEAALAQP	18398140	22	26	1	4137	
psoriasis	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	19663871	50	3	0	9741	in lesional, but not in nonlesional, plaque-type psoriatic skin
glioma		Cdkn1a	p21Cip1	P39689	12575	17 A3.3|17 15.12 cM	17.79	mouse	26400605	Y76-p		SLGLPKVyLSPGSRS	23007395	1	0	0		PDGF induced glioma in mice
leukemia	increased	Stat5a	STAT5A	P42230	20850	11 D|11 63.77 cM	90.83	mouse	448749	S725-p		TYMDQAPsPVVCPQP	24263804	16	1	0		
rheumatoid arthritis	decreased	FOXP3	FOXP3	Q9BZS1	50943	Xp11.23	47.24	human	27623902	S418-p		LEFRKKRsQRPSRCS	23396208	2	0	0		
diabetes mellitus	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	17272402	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
diabetes mellitus	decreased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	17272402	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
diabetes mellitus	decreased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	17272402	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
diabetes mellitus	decreased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	17272402	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
pancreatic carcinoma	decreased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448191	S727-p		NTIDLPMsPRTLDSL	18519681	145	53	67	9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994	
non-small cell lung adenocarcinoma	decreased	ERBB2	HER2	P04626	2064	17q12	137.91	human	447614	Y1248-p		PTAENPEyLGLDVPV	18687633	52	15	200	2244; 2247	
non-small cell lung adenocarcinoma	decreased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	448363	S465-p		HNPISSVs_______	18687633	10	20	59	12428; 11971; 9576; 9516; 85553; 13820	
non-small cell lung adenocarcinoma	decreased	IRS1	IRS1	P35568	3667	2q36.3	131.59	human	447562	S616-p		DDGYMPMsPGVAPVP	18687633	34	7	4	3203; 3193; 2386	
non-small cell lung adenocarcinoma	decreased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448056	Y1069-p		EDSFLQRySSDPTGA	18687633	37	18	117	2237	
non-small cell lung adenocarcinoma	decreased	SMAD1	SMAD1	Q15797	4086	4q31.21	52.26	human	448362	S463-p		SPHNPISsVS_____	18687633	10	13	58	12428; 11971; 9576; 9516; 85553; 13820	
type 2 diabetes	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	23516528	43	6	5		
ovarian cancer	increased	MYC	Myc	P01106	4609	8q24.21	48.80	human	17553985	Y74-p	Myc_N	SGLCSPSyVAVTPFS	23318434	2	0	0		
prostate cancer	decreased	AR	AR	P10275	367	Xq12	99.19	human	448415	S792-p	Hormone_recep	CVRMRHLsQEFGWLQ	23945560	5	0	0		high expression correlates with increased patient survival time from disease recurrence
prostate cancer	decreased	AR	AR	P10275	367	Xq12	99.19	human	448413	S310-p	Androgen_recep	TEDTAEYsPFKGGYT	23945560	10	5	0		high levels associated with greater patient survival time
non-small cell lung cancer	increased	ATF4	ATF-4	P18848	468	22q13.1	38.59	human	451446	S245-p		TRGSPNRsLPSPGVL	23975372	3	1	0		lymph node metastasis and advanced stages
hepatocellular carcinoma; B cell lymphoma; leukemia; non-small cell lung adenocarcinoma; angiosarcoma	mutation of site	Bub1b	BUB1B	Q9Z1S0	12236	2|2 E5	118.39	mouse	7761217	K243-ac		SRVGGALkAPGQSRG	23878276	4	0	0		mutated site develop cancers in mice
VHL	mutation of site	VHL	VHL	P40337	7428	3p25.3	24.15	human	22516600	S111-p	VHL	GTGRRIHsYRGHLWL	22071692	1	0	1		patient-derived S111 mutations cause the loss of tumor suppressor function in VHL; 
breast cancer	increased	ATF4	ATF-4	P18848	468	22q13.1	38.59	human	451446	S245-p		TRGSPNRsLPSPGVL	22052162	3	1	0		
SLE	increased	PRKCQ	PKCT	Q04759	5588	10p15.1	81.86	human	447907	T538-p	Pkinase	LGDAKTNtFCGTPDY	21983831	14	6	23	9379; 9377; 2060; 38938	activation of the KHS2-PKCT-IKK pathway controls SLE pathogenesis
colorectal carcinoma	increased	ELK1	ELK1	P19419	2002	Xp11.23	44.89	human	452139	T417-p		ISVDGLStPVVLSPG	23114923	6	0	1		
melanoma skin cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	1458614	K79-m3	Histone	REIAQDFkTDLRFQS	23227340	13	0	0	74073; 4260	melanomas wiith metastatic potential
melanoma skin cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	4710889	T80-p	Histone	EIAQDFKtDLRFQSS	23227340	1	15	23		melanomas wiith metastatic potential
Status epilepticus; CSWSS	mutation of site	GRIN2A	NMDAR2A	Q12879	2903	16p13.2	165.28	human	455471	Y1387-p	NMDAR2_C	GRCPSDPyKHSLPSQ	23933820	5	1	13		
leukemia	increased	Stat5a	STAT5A	P42230	20850	11 D|11 63.77 cM	90.83	mouse	448750	S779-p		DSLDARLsPPAGLFT	24263804	9	24	0		
CCM	mutation of site	CCM2	CCM2	Q9BSQ5	83605	7p13	48.84	human	4761921	S238-p		RAIFDGAsTPTHHLS	24466005	1	1	0		phosphorylation site
XLP	decreased	LCK	Lck	P06239	3932	1p35.2	58.00	human	447822	Y394-p	Pkinase_Tyr	RLIEDNEyTAREGAK	24688028	38	92	2957	6943; 2101	decrease upon restimulation of XLP patient T cells
Alzheimer's disease	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	14580829	S349-p		SSKEVDPsTGELQSL	24886973	17	0	1	95697; 16177	neurofibrillary tangles are positive for S349
stroke	decreased	Pygb	PYGB	G3V6Y6	25739	3q41	96.74	rat	456885	S15-p		SERQKQIsVRGIAGL	24858129	4	16	1		
MPPH1	mutation of site	CCND2	CCND2	P30279	894	12p13.32	33.07	human	469202	T280-p	Cyclin_C	DELDQAStPTDVRDI	24705253	4	2	11		
neurofibromatosis type 1	increased	Stat3	STAT3	P42227	20848	11 D|11 63.82 cM	88.05	mouse	448192	Y705-p		DPGSAAPyLKTKFIC	23318430	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	malignant peripheral nerve sheath tumors (MPNSTs)
neurofibromatosis type 1	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	23318430	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	malignant peripheral nerve sheath tumors (MPNSTs)
glioblastoma multiforme	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	13321500	T6-p	Histone	__ARTKQtARKSTGG	25553095	5	1	0		poor prognosis and overall survival
glioblastoma multiforme	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	455676	S10-p	Histone	TKQTARKsTGGKAPR	25553095	211	12	1	3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475	poor prognosis and overall survival
acute myelogenous leukemia; chronic lymphocytic leukemia	increased	Lyn	LYN	P25911	17096	4 A1|4 2.05 cM	58.81	mouse	454856	Y194-p	SH2	SLDNGGYyISPRITF	25587033	2	29	528		
obesity, hyperphagic	increased	Th	TH	P24529	21823	7 F5|7 88.06 cM	55.99	mouse	448545	S40-p	TOH_N	RFIGRRQsLIEDARK	16982425	54	10	11	2791	ob/ob mice
multiple myeloma	increased	KIF11	KIF11	P52732	3832	10q23.33	119.16	human	448410	T926-p	Microtub_bind	LDIPTGTtPQRKSYL	25660025	6	28	2		
X-linked agammaglobulinaemia	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	22366891	344	100	3046	6943; 2101	
X-linked agammaglobulinaemia	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447889	Y576-p	Pkinase_Tyr	RYMEDSTyYKASKGK	22366891	78	62	2523	3281	
X-linked agammaglobulinaemia	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447890	Y577-p	Pkinase_Tyr	YMEDSTYyKASKGKL	22366891	72	38	1747	3281	
X-linked agammaglobulinaemia	increased	LYN	LYN	P07948	4067	8q12.1	58.57	human	447624	Y508-p		YTATEGQyQQQP___	22366891	16	48	1560	2731	
X-linked agammaglobulinaemia	increased	SYK	Syk	P43405	6850	9q22.2	72.07	human	447661	Y525-p	Pkinase_Tyr	ALRADENyYKAQTHG	22366891	30	6	76	12081; 12967; 2711; 5514; 6485; 4349; 2710	
X-linked agammaglobulinaemia	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	451830	Y508-p	PI3K_P85_iSH2	QERYSKEyIEKFKRE	22366891	3	3	39		
X-linked agammaglobulinaemia	increased	VAV1	VAV1	P15498	7409	19p13.3	98.31	human	447866	Y174-p		EAEGDEIyEDLMRSE	22366891	18	1	0		
glioblastoma multiforme	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	10897613	Y41-p	Histone	GVKKPHRyRPGTVAL	25553095	6	3	4		poor prognosis and overall survival
type 2 diabetes	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18701453	361	6	1	9209; 9206; 97596; 9234; 9205	
mosaic variegated aneuploidy (MVA) syndrome	increased	KIF2A	KIF2A	O00139	3796	5q12.1	79.95	human	40240801	T554-p		ANRVKELtVDPTAAG	25660017	1	0	0		
Alzheimer's disease	increased	TRAPPC6A	TRAPPC6A	O75865	79090	19q13.32	17.60	human	23155168	S35-p	TRAPP	GGQKMSLsVLEGMGF	25650666	2	0	1		aggregates in human brain cortex
type 2 diabetes	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	15033922	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
type 2 diabetes	decreased	Gsk3a	GSK3A	Q2NL51	606496	7|7 A3	51.66	mouse	448584	S21-p		SGRARTSsFAEPGGG	15033922	137	22	277	8566; 9337; 9316; 9331; 5090; 9327; 8452	
type 2 diabetes	decreased	Insr	INSR	P15208	16337	8 A1.1|8 1.82 cM	155.61	mouse	447682	Y1180-p	Pkinase_Tyr	DIYETDYyRKGGKGL	15033922	38	14	107	3024; 2969	
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	15033922	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
type 2 diabetes	decreased	Insr	INSR	P15208	16337	8 A1.1|8 1.82 cM	155.61	mouse	447681	Y1179-p	Pkinase_Tyr	RDIYETDyYRKGGKG	15033922	40	36	707	3918; 3024; 2969	
Duchenne muscular dystrophy	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	448848	S2807-p		YNRTRRIsQTSQVSI	20615971	41	3	3		S2808A mutation reduces cardiomyopathy and mortality in mdx mice
type 2 diabetes; diabetes mellitus	decreased	Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	449111	S9-p		SGRPRTTsFAESCKP	20398714	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	A high fat diet and streptozotocin induced diabetes and decreased GSK3B S9 phosphorylation and increase tau phosphorylation. 
breast ductal carcinoma	decreased	EEF1A1	EEF1A1	P68104	1915	6q13	50.14	human	15629200	S300-p	GTP_EFTU_D2	EMHHEALsEALPGDN	20832312	1	5	0		
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455920	S588-p		RMRGRLGsVDSFERS	20938636	16	66	253	8730	
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455925	S318-p	PID	EFRSRCSsVTGVQRR	20938636	12	16	334	8619	
type 2 diabetes	decreased	TBC1D4	AS160	O60343	9882	13q22.2	146.56	human	455924	S751-p		EGRKRTSsTCSNESL	20938636	10	9	48		
type 2 diabetes	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	20938636	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	insulin-stimulated phosphorylation
thymic carcinoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	20597130	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	phosphorylation-positive patients show trend toward increased disease progression and poorer survival
acute myelogenous leukemia	decreased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447582	S37-p		YLDSGIHsGATTTAP	21156284	70	3	12	4270; 2009; 13537; 9561	The development of LSCs led to decreased nuclear phosphorylation of beta-catenin S37 and T41. 
acute myelogenous leukemia	decreased	Ctnnb1	CTNNB1	Q02248	12387	9 F4|9 72.19 cM	85.47	mouse	447583	T41-p		GIHSGATtTAPSLSG	21156284	59	3	0	4270; 13537; 9561; 9565	The development of LSCs led to decreased nuclear phosphorylation of beta-catenin S37 and T41. 
Parkinson's disease		AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21658387	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	Parkinson's disease associated mutations showed reduced interactions and phosphorylation of AKT1. 
hypertrophic cardiomyopathy	increased	Gata4	GATA4	P46152	54254	15p12	44.60	rat	450013	S261-p		IKPQRRLsASRRVGL	22227582	8	1	1		
hypertrophic cardiomyopathy	increased	Gata4	GATA4	P46152	54254	15p12	44.60	rat	449604	S105-p	GATA-N	AYTPPPVsPRFSFPG	22227582	13	0	0		
prostate cancer	increased	CALD1	Caldesmon	Q05682	800	7q33	93.23	human	448466	S789-p		QSVDKVTsPTKV___	22197205	19	18	0		
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19996208	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
melanoma skin cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	19996208	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
melanoma skin cancer	increased	GSK3A	GSK3A	P49840	2931	19q13.2	50.98	human	448584	S21-p		SGRARTSsFAEPGGG	19996208	137	22	277	8566; 9337; 9316; 9331; 5090; 9327; 8452	
melanoma skin cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	19996208	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	451837	S163-p	MARCKS	SFKLSGFsFKKSKKE	20211725	9	74	93	8722	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	447787	S156-p	MARCKS	KRFSFKKsFKLSGFS	20211725	22	28	7	11992; 2741	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	466360	S160-p	MARCKS	FKKSFKLsGFSFKKS	20211725	6	42	11	8722	
melanoma skin cancer	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	447786	S152-p	MARCKS	KKKKKRFsFKKSFKL	20211725	24	15	10	11992; 2741	
hypertrophic cardiomyopathy	increased	Hdac2	HDAC2	P70288	15182	10 19.44 cM|10 B1	55.30	mouse	449930	S394-p		EDAVHEDsGDEDGED	21576649	6	85	52		Phosphorylation of HDAC2 S394 is required for the development of cardiac hypertrophy.
Alzheimer's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	22278060	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	22278060	86	37	14		
MI	increased	PFN1	profilin 1	P07737	5216	17p13.2	15.05	human	450514	Y129-p	Profilin	GLINKKCyEMASHLR	23000962	4	26	658		
cardiomyopathy	increased	HDAC5	HDAC5	Q9UQL6	10014	17q21.31	121.98	human	4788487	S279-p		KVAERRSsPLLRRKD	20716686	6	18	1		inhibits cardiomyocyte hypertrophy
type 2 diabetes	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	20938636	207	14	33	5256; 2535; 4188; 50081; 2531	
hypertrophic cardiomyopathy	decreased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	470381	S1046-p	Tubulin-binding	KAQAKVGsLDNVGHL	20889984	2	87	1		associated with increased dephosphorylation
hypertrophic cardiomyopathy	decreased	Map4	MAP4	P27546	17758	9 F2|9 59.83 cM	117.43	mouse	1210622	S914-p	Tubulin-binding	SVRSKVGsTENIKHQ	20889984	3	51	41		associated with increased dephosphorylation
non-small cell lung cancer	increased	ECT2	ECT2	Q9H8V3	1894	3q26.31	103.50	human	483847	T359-p		YLYEKANtPELKKSV	21189248	2	17	8		
Crohn disease	decreased	RIPK2	RIPK2	O43353	8767	8q21.3	61.19	human	4270705	Y474-p	CARD	DLIMKEDyELVSTKP	21123652	3	1	0		
colorectal carcinoma	increased	ELAVL1	HuR	Q15717	1994	19p13.2	36.09	human	2246702	S318-p		GDKILQVsFKTNKSH	21310943	8	3	0		
lymphoma	mutation of site	Tp53	p53	P02340	22059	11 B3|11 42.83 cM	43.46	mouse	447530	S312-p		LPTCTSAsPPQKKKP	20962274	39	26	7	2528	S309AA mice are mor suseptible to lymphoma and liver tumors after IR exposure.
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21849493	42	5	0	23706	
PEL	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448313	S380-p		EPDHYRYsDTTDSDP	21819957	30	0	0	9551; 9554; 7960; 9549	
Kaposi's sarcoma	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448313	S380-p		EPDHYRYsDTTDSDP	21819957	30	0	0	9551; 9554; 7960; 9549	
Kaposi's sarcoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448092	S235-p		IAKRRRLsSLRASTS	21819957	167	57	972	5006; 4856; 4857; 4858; 4854; 27036; 4851; 5316; 34411; 3985; 4803; 8520; 2211; 3945; 9865; 14733; 62016	
Kaposi's sarcoma	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	21819957	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
Kaposi's sarcoma	increased	RPS6	S6	P62753	6194	9p22.1	28.68	human	448093	S236-p		AKRRRLSsLRASTSK	21819957	162	68	1124	5006; 4856; 4857; 4858; 4854; 27036; 4851; 5316; 34411; 3985; 4803; 8520; 2211; 3945; 9865; 14733; 62016	
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447860	S75-p	Bcl-2_BAD	EIRSRHSsYPAGTED	21849418	121	22	172	9291; 11865; 5193; 5284; 9296	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447862	S99-p	Bcl-2_BAD	PFRGRSRsAPPNLWA	21849418	118	53	216	9295; 5286; 4366	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
ovarian cancer	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447863	S118-p	Bcl-2_BAD	GRELRRMsDEFVDSF	21849418	45	62	166	9297	Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  
hepatocellular carcinoma	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448470	Y1234-p	Pkinase_Tyr	RDMYDKEyYSVHNKT	21455220	47	35	740	3129; 3077; 3126; 4091; 4033; 12468	
hepatocellular carcinoma	increased	MET	Met	P08581	4233	7q31.2	155.54	human	448471	Y1235-p	Pkinase_Tyr	DMYDKEYySVHNKTG	21455220	45	16	442	3129; 3077; 3126; 4091; 4033; 12468	
hepatocellular carcinoma	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447535	S392-p		FKTEGPDsD______	21455220	95	14	0	9281	
prostate cancer	increased	EIF4E	EIF4E	P06730	1977	4q23	25.10	human	447776	S209-p		DTATKSGsTTKNRFV	20679199	50	3	0	9741	hormone refractory human prostate cancer
prostate cancer	increased	Eif4e	EIF4E	P63073	13684	3 G3|3 64.3 cM	25.05	mouse	447776	S209-p		DTATKSGsTTKNRFV	20679199	50	3	0	9741	hormone refractory human prostate cancer
type 2 diabetes	decreased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	15919790	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448509	Y239-p		EEPPDHQyYNDFPGK	23277357	31	22	947	2434	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448511	Y313-p		ELFDDPSyVNIQNLD	23277357	42	89	1971	2431	
lung cancer	increased	Shc1	SHC1 iso2	P98083-2	20416	3 F1|3 39.11 cM	51.41	mouse	448510	Y240-p		EPPDHQYyNDFPGKE	23277357	28	22	943	2434	
Bloom's syndrome	increased	H2AFX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	17634426	195	29	29	2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312	
Bloom's syndrome	increased	CHEK2	Chk2	O96017	11200	22q12.1	60.91	human	447491	T68-p		SSLETVStQELYSIP	17634426	163	4	0	2661; 2197; 12812	
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	17653080	114	27	352	2236; 3777; 2234; 14565; 8543	
non-small cell lung cancer	mutation of site	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	452119	S768-p	Pkinase_Tyr	DEAYVMAsVDNPHVC	17653080	4	0	0		
Crohn disease	increased	Foxp3	FOXP3	Q99JB6	20371	X A1.1|X 3.41 cM	47.35	mouse	29672100	T175-p		CTFPRSGtPRKDSNL	23853094	1	1	0		
MI	decreased	Tnnt2	TNNT2	P50753	24837	13q13	35.73	rat	451755	S209-p	Troponin	KAQTERKsGKRQTER	23905701	9	0	0		
colorectal cancer	increased	PPP2CA	PPP2CA	P67775	5515	5q31.1	35.59	human	448571	Y307-p		VTRRTPDyFL_____	25003662	64	0	0		From 250 patient samples with metastatic CRC, 17.2% had high Y307-p levels and showed worse overall and progression-free survival. 
Crohn disease	increased	Foxp3	FOXP3	Q99JB6	20371	X A1.1|X 3.41 cM	47.35	mouse	12201088	S19-p		PSLALGPsPGVLPSW	23853094	1	1	0		
breast cancer	increased	AGO2	AGO2	Q9UKV8	27161	8q24.3	97.21	human	17533102	Y393-p	ArgoL2	ASFNTDPyVREFGIM	23636329	5	2	0		enhances cell survival and invasiveness under hypoxia and correlates with poorer overall survival in breast cancer patients
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	15193262	17	0	0		tamoxifen resistance
breast cancer	increased	ESR2	ER-beta	Q92731	2100	14q23.2-q23.3	59.22	human	34425602	Y36-p	ERbeta_N	SIYIPSSyVDSHHEY	24960160	2	0	0		Patients with p-Y36?negative tumors had shorter disease-free  and overall survival than those with p-Y36?positive tumors
breast cancer	increased	PLCG1	PLCG1	P19174	5335	20q12	148.53	human	447667	Y783-p		EGRNPGFyVEANPMP	22847294	69	40	558	25678; 2821; 14008; 14461; 88717	 higher distant relapse and shorter disease-free survival
breast cancer	increased	PLCG1	PLCG1	P19174	5335	20q12	148.53	human	448576	Y1253-p		EGSFESRyQQPFEDF	22847294	12	19	85		 higher distant relapse and shorter disease-free survival
ovarian epithelial carcinoma	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447887	Y397-p		SVSETDDyAEIIDEE	24655477	278	31	474	8556; 3283	High pY397 FAK is associated with improved overall survival
uteroplacental insufficiency	increased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447542	T203-p	Pkinase	HDHTGFLtEYVATRW	16940436	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
uteroplacental insufficiency	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	447562	S612-p		DDGYMPMsPGVAPVP	16940436	34	7	4	3203; 3193; 2386	
uteroplacental insufficiency	increased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447594	Y185-p	Pkinase	HTGFLTEyVATRWYR	16940436	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
uteroplacental insufficiency	increased	Mapk1	ERK2	P63086	116590	11q23	41.28	rat	447593	T183-p	Pkinase	HDHTGFLtEYVATRW	16940436	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
uteroplacental insufficiency	increased	Mapk3	ERK1	P21708	50689	1q36	43.08	rat	447543	Y205-p	Pkinase	HTGFLTEyVATRWYR	16940436	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	
diabetes mellitus	decreased	Nfe2l2	NRF2	Q60795	18024	2 C3|2 44.75 cM	66.90	mouse	450082	S40-p		SREVFDFsQRQKDYE	24967692	22	0	0		
glioma	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	24358106	344	100	3046	6943; 2101	
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	453434	S1097-p		GCRRRHSsETFSAPT	18952604	9	36	122	2385	ob/ob mice
obesity, hyperphagic	increased	Rps6kb1	p70S6K	Q8BSK8	72508	11|11 C	59.15	mouse	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18952604	361	6	1	9209; 9206; 97596; 9234; 9205	ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447566	S265-p		EFRPRSKsQSSSSCS	18952604	5	14	31		ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	450190	S302-p		TRRSRTEsITATSPA	18952604	37	10	1	2384; 2491	ob/ob mice
obesity, hyperphagic	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447506	S632-p		NGDYMPMsPKSVSAP	18952604	37	23	1	2388	ob/ob mice
kidney cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	19118035	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	renal cell carcinoma
kidney cancer	increased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	19118035	24	0	1		renal cell carcinoma
kidney cancer	decreased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448781	T198-p		PGLRRRQt_______	19118035	25	0	6		renal cell carcinoma
Status epilepticus	decreased	Slc12a5	KCC2 iso2	Q91V14-2	57138	2|2 H3	123.59	mouse	487533	S940-p	SLC12	ITDESRGsIRRKNPA	25733865	13	4	2		
hypertrophic cardiomyopathy		PTPN11	SHP-2 iso2	Q06124-2	5781	12q24.13	68.01	human	27458516	S189-p	SH2	GGGERFDsLTDLVEH	25802336	1	1	0		
hypertrophic cardiomyopathy		PTPN11	SHP-2 iso2	Q06124-2	5781	12q24.13	68.01	human	40407604	T73-p	SH2	YGGEKFAtLAELVQY	25802336	1	0	0		
pancreatic carcinoma	increased	GOT2	GOT2	P00505	2806	16q21	47.52	human	466485	K159-ac	Aminotran_1_2	SRDVFLPkPTWGNHT	25755250	1	8	32		
colorectal cancer	increased	BCL2	Bcl-2	P10415	596	18q21.33	26.27	human	448396	S87-p		AAAGPALsPVPPVVH	25826088	19	1	0		high pBcl-2-S87 had poor outcomes
prostate cancer	increased	RUNX2	AML3	Q13950	860	6p21.1	56.65	human	10892802	S312-p		SYLSQMTsPSIHSTT	25867060	11	1	0		
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	448853	S279-p		SSPTAPLsPMSPPGY	23922949	32	6	1		left ventricular hypertrophy
hypertrophic cardiomyopathy	increased	Gja1	GJA1	P08050	24392	20q11	43.03	rat	448854	S282-p		TAPLSPMsPPGYKLV	23922949	31	7	1		left ventricular hypertrophy
obesity, hyperphagic		Lepr	LEPR	P48356	16847	4 C6|4 46.96 cM	130.79	mouse	448435	Y985-p		QRQPSVKyATLVSND	20086094	14	0	0		
Turner-like syndrome	decreased	RAF1	RAF1	P04049	5894	3p25.2	73.05	human	447741	S259-p		SQRQRSTsTPNVHMV	20679480	50	31	142	9421	Noonan syndrome RAF1 mutations lead to dephosphorylation of S259 and impaired 14-3-3 binding.
fibrosarcoma of soft tissue	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	21575192	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	Y705 phosphorylation was significantly associated with tumor grade.
breast cancer	increased	ESR2	ER-beta	Q92731	2100	14q23.2-q23.3	59.22	human	447914	S105-p	ERbeta_N	LYAEPQKsPWCEARS	20696772	4	0	0		associated with improved disease-free and overall survival
colorectal carcinoma	increased	LEPR	LEPR	P48357	3953	1p31.3	132.49	human	448434	Y1141-p		SKKTFASyMPQFQTC	21166956	16	0	0		
colorectal carcinoma	increased	STAT3	STAT3	P40763	6774	17q21.2	88.07	human	448192	Y705-p		DPGSAAPyLKTKFIC	21166956	319	70	3065	9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075	
pancreatic cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	21474066	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	phosphorylation associated with poor overall survival
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	21474066	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	phosphorylation associated with poor overall survival
pancreatic cancer	increased	MTOR	mTOR	P42345	2475	1p36.22	288.89	human	447578	S2448-p		RSRTRTDsYSAGQSV	21474066	129	14	106	2971; 5536; 2976	phosphorylation associated with poor overall survival
Parkinson's disease	increased	PRKN	PARK2	O60260	5071	6q26	51.64	human	15624700	Y143-p		SPAGRSIyNSFYVYC	20823226	1	1	0		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471080	S284-p		AGGGRRIsDSHEDTG	20850451	26	5	28		
cardiomyopathy	decreased	MYBPC3	MYBPC3	Q14896	4607	11p11.2	140.76	human	471079	S275-p		LSAFRRTsLAGGGRR	20850451	20	5	14		
glioblastoma multiforme	increased	PTEN	PTEN	P60484	5728	10q23.31	47.17	human	448316	Y240-p	PTEN_C2	RREDKFMyFEFPQPL	22891331	3	1	0		shortened survival 
acute lymphocytic leukemia	increased	NR3C1	GR	P04150	2908	5q31.3	85.66	human	3178932	S134-p	GCR	ANLNRSTsVPENPKS	24291004	4	9	6	85060	glucocorticoid resistance
LGMD2A	decreased	CAPN3	CAPN3	P20807	825	15q15.1	94.25	human	36398901	S629-p	Calpain_u2	EEGKGKTsPDKQKQS	25252031	1	1	0		
Alzheimer's disease	increased	PPP1R1B	DARPP-32	Q9UD71	84152	17q12	22.96	human	448048	T75-p	DARPP-32	RPNPCAYtPPSLKAV	26178297	32	5	16	2301	
pancreatic carcinoma	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	25658205	21	74	114	3455; 4494	human pancreatic ductal adenocarcinoma
breast cancer	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	456477	S1417-p		INRERQKsLTLTPTR	25732845	7	17	1		
prostate cancer	increased	PTK2	FAK	Q05397	5747	8q24.3	119.23	human	447965	Y861-p		PIGNQHIyQPVGKPD	25868388	68	21	307		correlates with decreased survival
bladder cancer	decreased	YAP1	YAP1	P46937	10413	11q22.1	54.46	human	448847	S127-p		PQHVRAHsSPASLQL	26119935	76	29	180	13008; 29495; 4911; 57706	Yap phosphorylation decreased in cisplatin resistant tumors (xenograft model). 
endometrial cancer	increased	PAK4	PAK4	O96013	10298	19q13.2	64.07	human	448023	S474-p	Pkinase	KEVPRRKsLVGTPYW	26218748	8	64	140	3241	nuclear p-Pak4, pathogenesis of endometrial cancer especially in postmenopausal women
lung cancer		EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	1244153	S897-p		RVSIRLPsTSGSEGV	26158630	4	32	171	6347	co-localized with RSK, associated with overall survival of lung cancer patients
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	26272591	17	0	0		AKAP13 mRNA levels correlate with ER-alpha S305 phosphorylation and poor outcome in patients who received tamoxifen treatment  
hepatocellular carcinoma		STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448555	S25-p	Stathmin	QAFELILsPRSKESV	26505358	45	116	91		 there was a signifcant increase of stathmin expression in metastatic hepatic cancer, implying that the phosphorylation status of stathmin S25 may be involved in the invasion and metastasis of HCC
colorectal cancer	increased		PPAR-gamma iso2	P37231-2	5468	3p25	54.68	human	9256871	Y74-p	PPARgamma_N	YDLKLQEyQSAIKVE	26718225	2	0	1		
hepatocellular carcinoma	increased	SREBF1	SREBP-1	P36956	6720	17p11.2	121.68	human	53350800	R321-m2		APASAQSrGEKRTAH	26759235	1	1	0		correlates with poor prognosis
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	448515	T199-p		VKKSIRDtPAKNAQK	26993766	20	27	30	3541	
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449560	T237-p		KQEKTPKtPKGPSSV	26993766	6	25	21		
CRPC	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449024	T234-p		SFKKQEKtPKTPKGP	26993766	6	20	17		
breast cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	15382304	K561-m3	HSP70	EDEGLKGkISEADKK	26448330	2	5	2		
ovarian cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	3898759	K561-m2	HSP70	EDEGLKGkISEADKK	26448330	1	3	3		
ovarian cancer	increased	HSPA1A	HSP70	P0DMV8	3303	6p21.33	70.05	human	9300010	K561-m1	HSP70	EDEGLKGkISEADKK	26448330	0	4	17		
colorectal carcinoma; non-small cell squamous cell lung carcinoma	decreased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	25679763	207	14	33	5256; 2535; 4188; 50081; 2531	
multiple sclerosis	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	5891858	T357-p	Pkinase_Tyr	FELRKTQtSMSLGTT	25801023	5	0	1		MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	20536000	S14-p		LNVIKMKsSDFLESA	25801023	2	1	0		MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	27116401	S166-p	Pkinase_Tyr	LASFKMWsKLNNEEH	25801023	8	2	0	31122; 65746; 44590	MS brain samples
multiple sclerosis	increased	RIPK3	RIPK3	Q9Y572	11035	14q12	56.89	human	23003800	S227-p	Pkinase	VELPTEPsLVYEAVC	25801023	10	2	0	57220; 93654	MS brain samples
multiple sclerosis	increased	RIPK1	RIPK1	Q13546	8737	6p25.2	75.93	human	20536002	S15-p		NVIKMKSsDFLESAE	25801023	2	1	1		MS brain samples
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma	increased	CSNK2B	CK2B	P67870	1460	6p21.33	24.94	human	451751	S209-p		QAASNFKsPVKTIR_	25788269	6	44	58		
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma	increased	CDC37	CDC37	Q16543	11140	19p13.2	44.47	human	450034	S13-p	CDC37_N	VWDHIEVsDDEDETH	25788269	12	29	0	13248	
rheumatoid arthritis; SLE	increased	GRN	GRN	P28799	2896	17q21.31	63.54	human	41198100	S81-p	Granulin	IFTVSGTsSCCPFPE	26005049	1	0	0		
kidney cancer		CTTN	Cortactin	Q14247	2017	11q13.3	61.59	human	447702	Y421-p		RLPSSPVyEDAASFK	21696810	39	61	745	4569	correlated with sarcomatoid renal cell carcinoma
hypertrophic cardiomyopathy	increased	Gata4	GATA4	Q08369	14463	14 D1|14 33.24 cM	44.58	mouse	449604	S105-p	GATA-N	AYTPPPVsPRFSFPG	21746915	13	0	0		required for stress-induced cardiac hypertrophy
Duchenne muscular dystrophy	increased	Dag1	DAG1	Q62165	13138	9 F1|9 59.08 cM	96.90	mouse	449630	Y890-p	DAG1	PYRSPPPyVPP____	22810924	8	2	19		knockout of site ameliorates disease in mouse model
glioblastoma multiforme	increased	TNK2	Ack	Q07912	10188	3q29	114.57	human	4251154	Y635-p		PLPPPPAyDDVAQDE	25257795	1	2	5		
non-small cell squamous cell lung carcinoma	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	448082	S522-p		PASSAKTsPAKQQAP	26555036	20	47	84		CRMP2A is present within the nucleus in cancer cells
diabetes mellitus	increased	Oprm1	MOR-1	P33535	25601	1q11	44.49	rat	447785	T370-p		STRVRQNtREHPSTA	26713421	16	3	0		
obesity, hyperphagic		IRS2	IRS2	Q9Y4H2	8660	13q34	137.33	human	1984215	S391-p		SVAGSPLsPGPVRAP	26657864	3	37	80		
HNSCC	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448257	S232-p	E1_dh	NRYGMGTsVERAAAS	27498883	33	77	7		worse clinical outcome
tuberous sclerosis	increased	CTNND1	CTNND1	O60716	1500	11q12.1	108.17	human	450453	S268-p		PQVRVGGsSVDLHRF	27516388	11	71	56		
Alzheimer's disease	increased	Marcks	MARCKS	P26645	17118	10 B1|10 19.49 cM	29.66	mouse	454165	S46-p	MARCKS	VKVNGDAsPAAAEPG	27557632	1	40	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	484096	S147-p	MARCKS	DGATPSPsNETPKKK	27557632	1	33	3		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	9831684	S132-p	MARCKS	EAASAASsTSSPKAE	27557632	1	7	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	454165	S46-p	MARCKS	VKVNGDAsPAAAESG	27557632	1	40	0		
Alzheimer's disease	increased	MARCKS	MARCKS	P29966	4082	6q21	31.55	human	454166	T150-p	MARCKS	TPSPSNEtPKKKKKR	27557632	1	68	8		
breast cancer	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	27494834	124	8	3	9733; 4232; 5499; 12158; 4395; 14034; 40724	sites correlated and low expression associates with better survival in human breast cancers
breast cancer	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	27494834	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	sites correlated and low expression associates with better survival in human breast cancers
LBD	increased	DPYSL2	CRMP-2	Q16555	1808	8p21.2	62.29	human	454386	T514-p		SVTPKTVtPASSAKT	27609071	22	34	35	9397	
Parkinson's disease	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	449111	S9-p		SGRPRTTsFAESCKP	27609071	410	40	227	9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558	Parkinson's disease dementia
cardiomyopathy; hypertrophic cardiomyopathy	mutation of site	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	17620920	T1704-p	CAC1F_C	RAISGDLtAEEELDK	27864509	8	1	0		
cardiomyopathy; hypertrophic cardiomyopathy	mutation of site	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	4714250	S1700-p	CAC1F_C	PEIRRAIsGDLTAEE	27864509	13	6	0		
Parkinson's disease; LBD	decreased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	27609071	74	125	4206		Parkinson's disease dementia
leukemia	increased	ACAT1	ACAT1	P24752	38	11q22.3	45.20	human	10943316	Y407-p	Thiolase_C	HALKQGEyGLASICN	27867011	2	1	0		
mesothelioma	increased	NF2	Merlin	P35240	4771	22q12.2	69.69	human	448282	S518-p	ERM	DTDMKRLsMEIEKEK	18835652	27	39	1	9163; 13281	in patient samples, merlin was truncated or phosphorylated on S518
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	447728	S19-p	Crystallin	RPFFPFHsPSRLFDQ	24349305	24	15	2		increased at 12 weeks in all rat strains
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	448748	S45-p	Crystallin	FSTATSLsPFYLRPP	24349305	34	7	1		increased at 12 weeks in all rat strains
diabetes mellitus	increased	Cryab	CRYAB	P23928	25420	8q23	20.09	rat	448783	S59-p		PSFLRAPsWIDTGLS	24349305	42	20	0		increased at 12 weeks in all rat strains
HSAN1	mutation of site	SPTLC2	SPTLC2	O15270	9517	14q24.3	62.92	human	38520203	S384-p	Aminotran_1_2	FTKSFGAsGGYIGGK	25567748	1	0	0		
uteroplacental insufficiency	increased	Nr3c1	GR	P06536	24413	18p11	87.56	rat	447968	S232-p	GCR	PSKDTNEsPWRSDLL	16002560	33	5	0	4161	
type 2 diabetes	decreased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	16777975	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	db/db mice
type 2 diabetes	decreased	Foxo1	FOXO1A	Q9R1E0	56458	3 C|3 23.19 cM	69.52	mouse	448560	T24-p		LPRQRSCtWPLPRPE	16777975	50	5	39	2599; 9464	db/db mice
type 2 diabetes	increased	Irs1	IRS1	P35569	16367	1 C5|1 42.0 cM	130.72	mouse	447558	S307-p		TESITATsPASMVGG	16777975	66	13	0	2381	db/db mice
gastric carcinoma	increased	MORC2	MORC2	Q9Y6X9	22880	22q12.2	117.82	human	3217905	S739-p		ATPSRKRsVAVSDEE	25888627	2	36	8		associated with the poor prognosis of clinical gastric cancer
colorectal cancer	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	25860929	401	7	0	9235; 8695; 9284; 9286; 8514; 12571; 4030	FBXW7-mutations
Alzheimer's disease	increased	BACE1	BACE	P56817	23621	11q23.3	55.76	human	48881800	T252-p	Asp	YTGSLWYtPIRREWY	26317805	1	0	0		
ASD autism spectrum	mutation of site	UBE3A	UBE3A iso2	Q05086-2	7337	15q11.2	97.97	human	48891100	T485-p		MYSERRItVLYSLVQ	26255772	3	1	0		
psoriasis	increased	MAPK14	P38A	Q16539	1432	6p21.31	41.29	human	455799	Y323-p		DEPVADPyDQSFESR	24863062	8	1	0		
myelodysplastic syndrome	increased	ADD1	ADD1	P35611	118	4p16.3	80.96	human	449829	S726-p		KKKFRTPsFLKKSKK	26578796	19	55	158		
hypertrophic cardiomyopathy	increased	DPF3	DPF3 iso2	Q92784-2	8110	14q24.2	40.24	human	23251120	S348-p		GRRSGRGsPTADKKG	26582913	1	3	1		S348 phosphorylation is required for hypertrophy
T cell lymphoma	mutation of site	CARD11	CARD11	Q9BXL7	84433	7p22.2	133.28	human	5403700	S615-p		RYSFGPSsIHSSSSS	26551667	3	0	0		Sezary syndrome, cutaneous T cell lymphoma (CTCL)
multiple myeloma	increased	EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	457606	S21-p		CWRKRVKsEYMRLRQ	26517694	2	0	1		
stroke	increased	Stk4	MST1	Q9JI11	58231	2|2 H3	55.54	mouse	463558	Y433-p	Mst1_SARAH	KIPQDGDyEFLKSWT	26721416	2	11	110		inhibition protects against ischemic stroke
microlissencephaly		NDE1	NUDE1	Q9NXR1	54820	16p13.11	38.81	human	467025	T246-p	NUDE_C	STGGTPLtPAARISA	21529751	2	13	31		T246 in maybe involved in disease
non-small cell lung adenocarcinoma	increased	SSFA2	SSFA2	P28290	6744	2q31.3	138.39	human	484806	S92-p		CRTPLGAsLDEQSSS	26947549	1	48	2		high levels of phosphorylation had significantly reduced relapse-free survival (p < 0.01)
breast cancer; breast cancer, triple negative	increased	SRC	Src	P12931	6714	20q11.23	59.83	human	448234	Y419-p	Pkinase_Tyr	RLIEDNEyTARQGAK	26923594	344	100	3046	6943; 2101	higher in basal subtype BC;TNBC
obesity, hyperphagic	increased	HIST1H2BB	H2B	P33778	3018	6p22.2	13.82	human	449903	S36-p	Histone	RKRSRKEsYSIYVYK	27151441	7	12	47		
obesity, hyperphagic	increased	HIST1H3A	H3	P68431	8350	6p22.2	15.27	human	1308913	K27-m3	Histone	LATKAARkSAPATGG	27151441	124	8	3	9733; 4232; 5499; 12158; 4395; 14034; 40724	
breast cancer	decreased	NOTCH1	Notch 1	P46531	4851	9q34.3	272.50	human	483083	T2511-p	DUF3454	VPEHPFLtPSPESPD	27335110	4	0	0		
breast cancer	decreased	TFRC	TfR	P02786	7037	3q29	84.87	human	448928	Y20-p		FGGEPLSyTRFSLAR	21859709	1	44	1048		enhances breast cancer cell survival
breast cancer	increased	CAMK2A	CAMK2A	Q9UQM7	815	5q32	54.09	human	447797	T286-p		SCMHRQEtVDCLKKF	27605043	126	30	72	12716	primary breast cancer and lymph node metastases tissues
SBMA	increased	AR	AR	P10275	367	Xq12	99.19	human	448416	S96-p	Androgen_recep	QQQGEDGsPQAHRRG	28003546	8	10	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012804	K339-ac	Filament	EEEGQSLkDEMARHL	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012802	K189-ac	Filament	ARLDLERkIESLEEE	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012803	K228-ac	Filament	HVELDVAkPDLTAAL	24312501	1	1	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012801	K154-ac	Filament	DLATVRQkLQDETNL	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	31012800	K95-ac	Filament	RFLEQQNkALAAELN	24312501	1	2	0		
ALS	increased	GFAP	GFAP	P14136	2670	17q21.31	49.88	human	4131824	K260-ac	Filament	AEEWYRSkFADLTDA	24312501	1	2	2		
neuroblastoma	increased	ESYT1	ESYT1	Q9BSJ8	23344	12q13.2	122.86	human	450610	Y822-p	C2	GTKHLSPyATLTVGD	24349301	0	35	1220		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
Down syndrome	increased	TP53	p53	P04637	7157	17p13.1	43.65	human	447490	S15-p	P53_TAD	PSVEPPLsQETFSDL	20696760	401	7	0	9235; 8695; 9284; 9286; 8514; 12571; 4030	
obesity, hyperphagic	increased	Sirt1	SIRT1	Q923E4	93759	10|10 B4	80.37	mouse	452899	S46-p		DGPGLGRsPGEPSAA	21540183	6	47	9	2314	obese mice
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21865317	42	5	0	23706	
SLE	increased	S100A9	S100A9	P06702	6280	1q21.3	13.24	human	455888	T113-p		KPGLGEGtP______	22230807	4	14	22		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	12620701	Y52-p	Oest_recep	DSSKPAVyNYPEGAA	20101225	1	0	0		
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	12620700	Y219-p	zf-C4	SIQGHNDyMCPATNQ	20101225	1	0	0		
non-Hodgkin's lymphoma	decreased	Tp53	p53	P02340	22059	11 B3|11 42.83 cM	43.46	mouse	447490	S18-p	P53_TAD	ISLELPLsQETFSGL	20145032	401	7	0	9235; 8695; 9284; 9286; 8514; 12571; 4030	
breast ductal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	16855100	S387-p	Peptidase_C14	YLEMDLSsPQTRYIP	20937773	5	2	0		
encephalopathy	increased	Dnm1l	DRP1	O35303	114114	11q23	83.91	rat	454690	S635-p		PIPIMPAsPQKGHAV	21119009	21	74	114	3455; 4494	
ASD autism spectrum	decreased	FMR1	FMR1	Q06787	2332	Xq27.3	71.17	human	469583	S500-p	FXMRP1_C_core	NSEASNAsETESDHR	24180586	17	6	0		reduction of phosphorylated FMR1 in superior frontal cortex in children and adults with autism, a reduction also seen in Brodman area in adults, but not in children
ovarian cancer		SH2B3	LNK	Q9UQQ2	10019	12q24.12	63.23	human	14575499	S150-p		RHIFRRRsAGELPAA	24704825	0	22	4		
breast cancer, triple negative	increased	PELP1	PELP1	Q8IZL8	27043	17p13.2	119.70	human	472322	S1033-p		LAPEALPsQGEVERE	25788226	2	14	29		
AC	mutation of site	DSP	Desmoplakin	P15924	1832	6p24.3	331.77	human	34833301	R2834-me		SGSRSGSrSGSRSGS	25733715	1	1	0		
colorectal cancer	increased	FER	Fer	P16591	2241	5q21.3	94.64	human	448461	Y714-p	Pkinase_Tyr	RQEDGGVySSSGLKQ	25867068	3	34	611		
prostate cancer	increased	TLN1	talin 1	Q9Y490	7094	9p13.3	269.77	human	1984203	S425-p		TMLEDSVsPKKSTVL	24793790	5	43	2	13589; 5426	promotes bone metastasis
breast adenocarcinoma	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447860	S75-p	Bcl-2_BAD	EIRSRHSsYPAGTED	24909179	121	22	172	9291; 11865; 5193; 5284; 9296	Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance
breast adenocarcinoma	increased	BAD	BAD	Q92934	572	11q13.1	18.39	human	447862	S99-p	Bcl-2_BAD	PFRGRSRsAPPNLWA	24909179	118	53	216	9295; 5286; 4366	Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance
type 2 diabetes	increased	Gria1	GluR1	P19490	50592	10q22	101.58	rat	448565	S849-p		FCLIPQQsINEAIRT	23490331	77	3	3	75574	
type 2 diabetes	increased	Syn1	SYN1	P09951	24949	Xq11	73.99	rat	450236	S603-p		AGPIRQAsQAGPGPR	23490331	18	9	11	88246	
type 2 diabetes	decreased	Camk2a	CAMK2A	P11275	25400	18q12.1	54.11	rat	447797	T286-p		SCMHRQEtVDCLKKF	23490331	126	30	72	12716	
type 2 diabetes	decreased	Camk2b	CAMK2B	P08413	24245	14q21	60.40	rat	450048	T287-p		SMMHRQEtVECLKKF	23490331	16	15	109	12716	
Status epilepticus	increased	Ywhaz	14-3-3 zeta	P63101	22631	15|15 B3.1	27.77	mouse	449833	S58-p	14-3-3	VVGARRSsWRVVSSI	20813501	14	0	5		
breast cancer	increased	TWIST1	TWIST1	Q15672	7291	7p21.1	20.95	human	18905000	S68-p		GGGDEPGsPAQGKRG	21502402	3	12	0		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	21562258	42	5	0	23706	
acute myelogenous leukemia	mutation of site	CBL	CBL	P22681	867	11q23.3	99.63	human	449753	Y371-p		TQEQYELyCEMGSTF	20622007	6	9	81		
PAAND	mutation of site	MEFV	pyrin	O15553	4210	16p13.3	86.44	human	455899	S242-p		SGKMRPRsLEVTIST	27030597	4	6	0		
ASD autism spectrum	decreased	NLGN4X	NLGN4X	Q8N0W4	57502	Xp22.32-p22.31	91.92	human	40245512	T707-p		KDKRRHEtHRRPSPQ	25675530	1	1	0		phosphorylation of this site is eliminated in individuals carrying the autism-associated mutation R704C
T-ALL	increased	IRAK1	IRAK1	P51617	3654	Xq28	76.54	human	450949	T209-p		LCEISRGtHNFSEEL	26068967	2	1	0		
NAFLD	increased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	457552	S193-p		PPPHPHAsPAHLAAP	27373160	12	0	0		
Parkinson's disease	decreased	CRTC1	TORC1	Q6UUV9	23373	19p13.11	67.30	human	60885604	S215-p	TORC_M	KTGSRPKsCEVPGIN	27903866	1	0	0		
ovarian cancer	increased	Syk	Syk	P48025	20963	13 A5|13 27.41 cM	71.38	mouse	447662	Y520-p	Pkinase_Tyr	LRADENYyKAQTHGK	26096845	30	7	72	12081; 12967; 2711; 5514; 6485; 4349; 2710	increased in recurrent ovarian cancers
ovarian cancer	increased	Syk	Syk	P48025	20963	13 A5|13 27.41 cM	71.38	mouse	447661	Y519-p	Pkinase_Tyr	ALRADENyYKAQTHG	26096845	30	6	76	12081; 12967; 2711; 5514; 6485; 4349; 2710	increased in recurrent ovarian cancers
melanoma skin cancer	increased	Akt1	Akt1	P31750	11651	12 F1|12 61.2 cM	55.71	mouse	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	26565903	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	activated AKT1 promotes melanoma formation and distant metastasis
breast cancer	increased	FOSL1	FRA1	P15407	8061	11q13.1	29.41	human	1270902	T217-p		LEPEALHtPTLMTTP	27816489	2	0	0		
myotonic dystrophy type1	increased	CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	8	1		DM1-E2 (classic phenotype)
myotonic dystrophy type1		CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	8	1		DM1-E1, DM1-CDM, no change
DM2		CELF1	CELF1	Q92879	10658	11p11.2	52.06	human	3347300	S28-p	RRM_1	GQVPRTWsEKDLREL	24376746	3	8	1		DM2-PS, DM2-PDM, DM2-PROMM no change
neuroblastoma	increased	ADAM9	ADAM9	Q13443	8754	8p11.22	90.56	human	457836	Y736-p		RKKRSQTyESDGKNQ	24349301	0	3	47		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	ANTXR1	ANTXR1	Q9H6X2	84168	2p13.3	62.79	human	458176	Y425-p	Ant_C	VKMPEQEyEFPEPRN	24349301	1	11	108		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	ANKRD26	ANKRD26	Q9UPS8	22852	10p12.1	196.41	human	462968	Y296-p		RKNLEATyGTVRTGN	24349301	0	11	67		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	APP	APP	P05067	351	21q21.3	86.94	human	448202	Y757-p	APP_amyloid	SKMQQNGyENPTYKF	24349301	11	19	864		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CD46	CD46 iso4	P15529-4	4179	1q32.2	41.36	human	451710	Y357-p		GGAEYATyQTKSTTP	24349301	0	18	604		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK2	CDK2	P24941	1017	12q13.2	33.93	human	447740	Y15-p	Pkinase	EKIGEGTyGVVYKAR	24349301	31	126	3845		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK5	CDK5	Q00535	1020	7q36.1	33.30	human	448022	Y15-p	Pkinase	EKIGEGTyGTVFKAK	24349301	15	47	894		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CD46	CD46 iso2	P15529-2	4179	1q32.2	44.24	human	451710	Y387-p		GGAEYATyQTKSTTP	24349301	0	18	604		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447610	Y15-p	Pkinase	EKIGEGTyGVVYKGR	24349301	150	139	3902	4539; 14566; 9111	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447608	T14-p	Pkinase	IEKIGEGtYGVVYKG	24349301	23	115	1764	2543	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CTNND1	CTNND1	O60716	1500	11q12.1	108.17	human	449495	Y96-p		QDHSHLLySTIPRMQ	24349301	4	35	735		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CNNM3	CNNM3	Q8NE01	26505	2q11.2	76.12	human	467057	Y301-p		ARGGGDPySDLSKGV	24349301	0	5	125		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	JUP	CTNNG	P14923	3728	17q21.2	81.74	human	461979	Y480-p		QNSVRLNyGIPAIVK	24349301	0	4	118		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	DDR2	DDR2	Q16832	4921	1q23.3	96.74	human	456862	Y740-p	Pkinase_Tyr	RNLYSGDyYRIQGRA	24349301	1	9	366		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	DDR2	DDR2	Q16832	4921	1q23.3	96.74	human	456861	Y736-p	Pkinase_Tyr	FGMSRNLySGDYYRI	24349301	1	9	409		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	EPHA2	EphA2	P29317	1969	1p36.13	108.27	human	450861	Y772-p	Pkinase_Tyr	EDDPEATyTTSGGKI	24349301	2	55	860	8244; 8862	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	EIF3C	EIF3C	Q99613	8663	16p11.2	105.34	human	459507	Y881-p		FDHKQGTyGGYFRDQ	24349301	0	7	118		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	CCDC88A	girdin	Q3V6T2	55704	2p16.1	216.04	human	450762	Y1799-p		QSKDSNPyATLPRAS	24349301	4	12	137		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	FGFR2	FGFR2	P21802	2263	10q26.13	92.03	human	472824	Y656-p	Pkinase_Tyr	RDINNIDyYKKTTNG	24349301	1	8	66		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	GSK3B	GSK3B	P49841	2932	3q13.33	46.74	human	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	24349301	74	125	4206		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	HIST1H2BJ	HIST1H2BJ	P06899	8970	6p22.1	13.90	human	21691325	Y43-p	Histone	ESYSIYVyKVLKQVH	24349301	0	6	33		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	HNRNPM	hnRNP M	P52272	4670	19p13.2	77.52	human	456974	Y64-p	HnRNP_M	GGNRFEPyANPTKRY	24349301	0	14	264		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	LYN	LYN	P07948	4067	8q12.1	58.57	human	448695	Y397-p	Pkinase_Tyr	RVIEDNEyTAREGAK	24349301	20	60	2054	6943; 2101	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	448386	Y1161-p	Pkinase_Tyr	FGMTRDIyETDYYRK	24349301	16	31	455	80732; 3021	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MAPK12	P38G	P53778	6300	22q13.33	41.94	human	448032	Y185-p	Pkinase	ADSEMTGyVVTRWYR	24349301	2	33	804		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	IGF1R	IGF1R	P08069	3480	15q26.3	154.79	human	448387	Y1165-p	Pkinase_Tyr	RDIYETDyYRKGGKG	24349301	13	38	707	3918; 3024; 2969	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	JAK2	JAK2	O60674	3717	9p24.1	130.67	human	451494	Y570-p	Pkinase_Tyr	VRREVGDyGQLHETE	24349301	9	39	825		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MYH10	MYH10	P35580	4628	17p13.1	229.00	human	463833	Y1415-p	Myosin_tail_1	LEEKALAyDKLEKTK	24349301	0	12	449		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TMIGD2	IGPR-1	Q96BF3	126259	19p13.3	30.67	human	463789	Y222-p		DQRGQSIySTSFPQP	24349301	0	3	126		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MAP4K5	KHS1	Q9Y4K4	11183	14q22.1	95.02	human	463541	Y31-p	Pkinase	QRVGSGTyGDVYKAR	24349301	0	7	161		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	INSR	INSR	P06213	3643	19p13.2	156.33	human	447680	Y1185-p	Pkinase_Tyr	FGMTRDIyETDYYRK	24349301	34	31	455	80732; 3021	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TMIGD2	IGPR-1 iso2	Q96BF3-2	126259	19p13.3	30.32	human	3422796	Y188-p		RDSGNAFySNVLYRP	24349301	0	3	117		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	INSR	INSR	P06213	3643	19p13.2	156.33	human	447681	Y1189-p	Pkinase_Tyr	RDIYETDyYRKGGKG	24349301	40	36	707	3918; 3024; 2969	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	UNK	UNK	Q9C0B0	85451	17q25.1	88.08	human	3663342	Y232-p		PRLCRQGyACPYYHN	24349301	0	1	3		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RBMX	RBMX	P38159	27316	Xq26.3	42.33	human	460084	Y255-p		HSSSRDDyPSRGYSD	24349301	0	7	70		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	MPZL1	PZR	O95297	9019	1q24.2	29.08	human	449521	Y263-p		NKSESVVyADIRKN_	24349301	1	57	1101	5543; 8088	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TLN2	talin 2	Q9Y4G6	83660	15q22.2	271.61	human	462871	Y72-p	FERM_f0	EAGRTLDyYMLRNGD	24349301	0	5	19		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	VIM	Vimentin	P08670	7431	10p13	53.65	human	448931	Y61-p	Filament_head	ASSPGGVyATRSSAV	24349301	0	50	2170		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SH2D3C	SHEP1	Q8N5H7	10044	9q34.11	94.41	human	460469	Y316-p		EQSGAIIyCPVNRTF	24349301	0	2	22		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PCDH1	PCDH1	Q08174	5097	5q31.3	114.74	human	2470209	Y897-p	Protocadherin	KKETKDLyAPKPSGK	24349301	0	7	63		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SRCIN1	SNIP	Q9C0H9	80725	17q12	112.45	human	456704	Y268-p		LVKGEGLyADPYGLL	24349301	1	18	217		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PLD3	PLD3	Q8IV08	23646	19q13.2	54.71	human	3424010	Y7-p		_MKPKLMyQELKVPA	24349301	0	6	127		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
breast cancer		Mdm2	MDM2	P23804	17246	10 D2|10 66.32 cM	54.56	mouse	448131	S183-p		RHRKRRRsLSFDPSL	20841468	12	8	2		
breast cancer		Mdm2	MDM2	P23804	17246	10 D2|10 66.32 cM	54.56	mouse	448130	S163-p		SSRRRSIsETEENTD	20841468	39	19	5	3521	
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448102	S167-p	Oest_recep	GGRERLAsTNDKGSM	24166501	38	5	0	42101; 64508	S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients
breast cancer	increased	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448805	S305-p		IKRSKKNsLALSLTA	24166501	17	0	0		S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients
Alzheimer's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	31872528	S40-p	Dynamin_N	TQSSGKSsVLESLVG	25192600	1	1	0		blocking phosphorylation is neuroprotective in models
Alzheimer's disease	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	31866197	S44-p	Dynamin_N	GKSSVLEsLVGRDLL	25192600	1	1	0		blocking phosphorylation is neuroprotective in models
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	25637461	42	5	0	23706	Lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.
neuroblastoma	increased	SDC2	syndecan-2	P34741	6383	8q22.1	22.16	human	448376	Y191-p	Syndecan	RKPSSAAyQKAPTKE	24349301	1	5	6		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PPP1CB	PPP1CB	P62140	5500	2p23.2	37.19	human	459361	Y306-p		EKKAKYQyGGLNSGR	24349301	0	8	318		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RAB8A	RAB8A	P61006	4218	19p13.11	23.67	human	464116	Y5-p		___MAKTyDYLFKLL	24349301	0	7	76		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TNS2	tensin 2	Q63HR2	23371	12q13.13	152.58	human	450768	Y483-p		GPLDGSPyAQVQRPP	24349301	1	44	1536		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	TXNRD1	TRXR1	Q16881	7296	12q23.3	70.91	human	450592	Y281-p	Pyr_redox_2	KVVYENAyGQFIGPH	24349301	0	21	566		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	F2R	PAR1	P25116	2149	5q13.3	47.44	human	458505	Y420-p		SNLNNSIyKKLLT__	24349301	0	6	121		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SHC3	SHC3	Q92529	53358	9q22.1	64.06	human	451257	Y406-p		RQGSSDIySTPEGKL	24349301	1	3	27		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	RPL35A	RPL35A	P18077	6165	3q29	12.54	human	487362	Y34-p	Ribosomal_L35Ae	LLKIEGVyARDETEF	24349301	0	7	42		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	SCARF2	SREC-II	Q96GP6	91179	22q11.21	92.38	human	450727	Y628-p		EGPGGALyARVARRE	24349301	0	11	74		increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
neuroblastoma	increased	PRKCD	PKCD	Q05655	5580	3p21.1	77.51	human	447573	Y313-p		SSEPVGIyQGFEKKT	24349301	35	58	1707	2055	increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
vulvar cancer	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447610	Y15-p	Pkinase	EKIGEGTyGVVYKGR	25849598	150	139	3902	4539; 14566; 9111	vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
vulvar cancer	increased	CDK1	CDK1	P06493	983	10q21.2	34.10	human	447609	T161-p	Pkinase	GIPIRVYtHEVVTLW	25849598	24	40	83	9114	vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
vulvar cancer	increased	CCNB1	CCNB1	P14635	891	5q13.2	48.34	human	448814	S126-p		PILVDTAsPSPMETS	25849598	11	2	0		vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449132	S701-p		DTSPRHLsNVSSTGS	25394490	13	9	5		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447933	T497-p		SSPGSPGtPGSRSRT	25394490	73	20	26	49561	In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447934	T504-p		TPGSRSRtPSLPTPP	25394490	36	13	5		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449081	S688-p		GAEIVYKsPVVSGDT	25394490	116	41	90	9632	In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	447930	S554-p	Tubulin-binding	NVRSKIGsTENLKHQ	25394490	84	19	2		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449080	S527-p		VVRTPPKsPSASKSR	25394490	39	33	25		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449104	S648-p	Tubulin-binding	RVQSKIGsLDNITHV	25394490	24	21	0		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449083	S714-p		GSIDMVDsPQLATLA	25394490	32	6	0		In midbrain, significant hyperphosphorylation in PD mouse model
Parkinson's disease	increased	Mapt	Tau	P10637	17762	11 67.79 cM|11 E1	76.24	mouse	449082	S696-p		PVVSGDTsPRHLSNV	25394490	102	48	69	35834; 20194	In midbrain, significant hyperphosphorylation in PD mouse model
prostate cancer	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	454787	S272-p		RSRLTPVsPESSSTE	26279575	3	77	278	13121	
prostate cancer	increased	SQSTM1	SQSTM1	Q13501	8878	5q35.3	47.69	human	457004	T269-p		GGKRSRLtPVSPESS	26279575	3	71	136	13121	
hyperalgesia	increased	Trpv1	TRPV1	O35433	83810	10q24	94.95	rat	473576	T406-p		IAYSSSEtPNRHDML	26376215	4	0	0		
chronic myelogenous leukemia	increased	YBX3	CSDA	P16989	8531	12p13.2	40.09	human	3181076	S134-p	CSD	NPRKYLRsVGDGETV	21368869	1	30	1		
breast cancer	increased	SIRT6	SIRT6	Q8N6T7	51548	19p13.3	39.12	human	7916000	S338-p		PKRERPTsPAPHRPP	25074979	2	7	23		poorer overall survival
breast cancer	decreased	CDKN1B	p27Kip1	P46527	1027	12p13.1	22.07	human	448645	T157-p		GIRKRPAtDDSSTQN	26701207	24	0	1		correlates with low level of Myc protein
pheochromocytoma	mutation of site	RET	Ret	P07949	5979	10q11.21	124.32	human	455479	Y791-p	Pkinase_Tyr	HPHVIKLyGACSQDG	20080836	2	0	0		double C634Y/Y791F mutant
AIS	mutation of site	AR	AR	P10275	367	Xq12	99.19	human	23303205	R407-p	Androgen_recep	AAAAAQCrYGDLASL	22334658	1	0	0		
hypertrophic cardiomyopathy	mutation of site	JPH2	JPH2	Q9BR39	57158	20q13.12	74.22	human	12275224	Y141-p	MORN	TNGMRHGyGVRQSVP	22389502	1	0	0		Y141H
breast cancer, triple negative	increased	TAB3	TAB3	Q8N5C8	257397	Xp21.2	78.68	human	54400803	S408-gl		TATTPPSsSPSRGIS	27009840	1	2	0		cancer metastasis and poor prognosis
breast cancer	increased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	27130664	43	108	166	4191; 3426	higher incidence of recurrence
anal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	56640300	T273-p	Peptidase_C14	DAGALTTtFEELHFE	27325299	3	0	0		overall survival (OS) was superior for tumors showing a high pT273 caspase-8 signal 
Alzheimer's disease	increased	FCGR2B	FCGR2B iso2	P31994-2	2213	1q23.3	31.94	human	448507	Y273-p		GAENTITySLLMHPD	27834631	4	2	1		
melanoma skin cancer; cancer, squamous cell carcinoma; BCC	increased	NFATC4	NFAT3	Q14934	4776	14q12	95.45	human	31859079	S259-p		APGPTPAsPRPASPC	27893713	1	1	0		
Alzheimer's disease	decreased	Hist1h3a	H3	P68433	360198	13|13 A3.1	15.27	mouse	481136	S57-p	Histone	EIRRYQKsTELLIRK	26199864	2	18	9		 done in 5XFAD (rapid amyloid deposition ) mice
ALS	increased	TARDBP	TDP-43	Q13148	23435	1p36.22	44.74	human	3084616	S409-p		GSSMDSKsSGWGM__	26192745	35	1	0		
Alzheimer's disease	decreased	Hist1h3a	H3	P68433	360198	13|13 A3.1	15.27	mouse	481137	T58-p	Histone	IRRYQKStELLIRKL	26199864	1	9	0		 done in 5XFAD (rapid amyloid deposition ) mice
chronic myelogenous leukemia	decreased	MAPK8	JNK1	P45983	5599	10q11.22	48.30	human	447643	T183-p	Pkinase	AGTSFMMtPYVVTRY	26147002	232	32	392	4306; 5136; 4668; 4671; 9257; 9255; 5755; 9251	
chronic myelogenous leukemia	decreased	SFN	14-3-3 sigma	P31947	2810	1p36.11	27.77	human	456054	S186-p	14-3-3	FHYEIANsPEEAISL	26147002	5	0	0		
chronic lymphocytic leukemia; mantle cell lymphoma	increased	ALOX5	5-LO	P09917	240	10q11.21	77.98	human	452140	S524-p	Lipoxygenase	GMRGRKSsGFPKSVK	26210919	7	0	0		
HNSCC	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447981	T356-p		DSFETQRtPRKSNLD	26265441	12	17	36		
colorectal carcinoma; ovarian cancer; non-small cell lung adenocarcinoma, surrounding tissue	increased	TOP1	TOP1	P11387	7150	20q12	90.73	human	27276101	S506-p	Topoisom_I	ADTVGCCsLRVEHIN	26248194	3	0	0		
Fanconi's anaemia	decreased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448554	S16-p	Stathmin	KELEKRAsGQAFELI	26466335	32	94	61	3353	
Fanconi's anaemia	decreased	STMN1	STMN1	P16949	3925	1p36.11	17.30	human	448556	S38-p	Stathmin	SVPEFPLsPPKKKDL	26466335	43	108	166	4191; 3426	
hepatocellular carcinoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449560	T237-p		KQEKTPKtPKGPSSV	26536659	6	25	21		
hepatocellular carcinoma	increased	NPM1	NPM1	P06748	4869	5q35.1	32.58	human	449024	T234-p		SFKKQEKtPKTPKGP	26536659	6	20	17		
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	26676747	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	high BAP28  or low AktT308 increased survival and response to gemcitabine
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	451537	Y267-p		SQYGQEVyDTPPMAV	26867768	3	22	285		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	448779	Y306-p		PSNHHAVyDVPPSVS	26867768	3	15	191		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	451538	Y287-p		RDPLLEVyDVPPSVE	26867768	2	17	284		driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	448721	Y249-p		APGPQDIyDVPPVRG	26867768	11	43	723	4014	driving mammary carcinoma progression
breast cancer	increased	BCAR1	P130Cas	P56945	9564	16q23.1	93.37	human	449639	Y234-p		AQPEQDEyDIPRHLL	26867768	3	30	698		driving mammary carcinoma progression
RTT	mutation of site	MECP2	MECP2	P51608	4204	Xq28	52.44	human	31879716	T158-p	MBD	DPNDFDFtVTGRGSP	27064487	1	0	0		
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3546424	Y39-p	Synuclein	KTKEGVLyVGSKTKE	27348587	4	2	11		accumulates in Lewy bodies
cystic fibrosis	mutation of site	CFTR	CFTR	P13569	1080	7q31.2	168.14	human	56689900	S1045-p	ABC_membrane	QQLKQLEsEGRSPIF	27261451	1	0	0		S1045Y-CFTR mutation
non-small cell lung adenocarcinoma	increased	Mybl2	B-Myb	P48972	17865	2 H2|2 84.0 cM	79.10	mouse	452027	T490-p	Cmyb_C	SQKVVVTtPLHRDKT	27212033	3	2	43		
non-small cell lung adenocarcinoma	increased	MYBL2	B-Myb	P10244	4605	20q13.12	78.76	human	452027	T487-p	Cmyb_C	SQKVVVTtPLHRDKT	27212033	3	2	43		
hypertrophic cardiomyopathy	decreased	NOX4	NOX4	Q9NPH5	50507	11q14.3	66.93	human	57848101	Y566-p		LSNQNNSyGTRFEYN	27525436	1	1	0		
atherosclerosis		NR1H3	LXR-alpha	Q13133	10062	11p11.2	50.40	human	469114	S198-p		SLPPRASsPPQILPQ	25825525	4	0	0		
Alzheimer's disease	decreased	WWOX	WWOX	Q9NZC7	51741	16q23.1-q23.2	46.68	human	449043	Y33-p	WW	TTKDGWVyYANHTEE	15126504	19	0	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447927	S199-p		GDRSGYSsPGSPGTP	15126504	70	26	33	29957	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	15126504	86	37	14		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449551	S198-p		SGDRSGYsSPGSPGT	15126504	19	13	10		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447934	T212-p		TPGSRSRtPSLPTPP	15126504	36	13	5		
Alzheimer's disease	increased	APP	APP	P05067	351	21q21.3	86.94	human	480465	S679-p	Beta-APP	DAEFRHDsGYEVHHQ	25556395	7	0	0		accumulation in the parenchyma and vasculature and is largely restricted to late-stage AD
obesity, hyperphagic	increased	Irs1	IRS1	P35570	25467	9q34	131.18	rat	447558	S307-p		TESITATsPASMVGG	16267124	66	13	0	2381	
obesity, hyperphagic	increased	Ppp1r12a	MYPT1	Q10728	116670	7q21	115.28	rat	448587	T697-p		ARQSRRStQGVTLTD	16267124	54	40	226	5163	
obesity, hyperphagic	decreased	Akt1	Akt1	P47196	24185	6q32	55.74	rat	447856	T308-p	Pkinase	KDGATMKtFCGTPEY	16267124	580	10	18	43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038	
hepatocellular carcinoma		H2AFX	H2AX	P16104	3014	11q23.3	15.01	human	448841	S139-p		GKKATQAsQEY____	25537504	195	29	29	2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312	recurrence/metastasis of HCC
non-small cell lung cancer	increased	PAK1	PAK1	Q13153	5058	11q13.5-q14.1	60.65	human	448177	T423-p	Pkinase	PEQSKRStMVGTPYW	25956913	32	3	11	2601	Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression 
non-small cell lung cancer	increased	CRK	CRK	P46108	1398	17p13.3	33.83	human	454189	S41-p	SH2	VFLVRDSsTSPGDYV	25956913	2	17	17		Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression 
colorectal cancer		COPS6	COPS6	Q7L5N1	10980	7q22.1	36.16	human	48903200	S148-p	JAB	QVCEIIEsPLFLKLN	26267535	1	0	0		
breast cancer, triple negative		EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	10417699	T416-p		EANSRCQtPIKMKPN	26279746	2	5	7		
breast cancer	decreased	VASP	VASP	P50552	7408	19q13.32	39.83	human	469024	S322-p		TTLPRMKsSSSVTTS	26336132	3	15	45		Patients with high expression of PRKD2 showed an increase in relapse-free survival.
anal carcinoma	increased	CASP8	CASP8	Q14790	841	2q33.1	55.39	human	56640300	T273-p	Peptidase_C14	DAGALTTtFEELHFE	27462786	3	0	0		elevated levels of Plk3 and pT273 caspase-8  are correlated with favorable clinical outcome with  mitomycin C-based chemoradiotherapy (CRT)
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951801	K156-m1	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951800	K156-ub	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
bladder cancer	mutation of site	POU5F1	Oct4	Q01860	5460	6p21.33	38.57	human	57951802	K156-ac	Pou	FAKLLKQkRITLGYT	27369080	1	1	0		
FXS	mutation of site	FMR1	FMR1	Q06787	2332	Xq27.3	71.17	human	4046001	R546-me		RGQGGRGrGGGFKGN	10518318	5	0	0		arginine to a histidine
glioblastoma multiforme	increased	CDC25A	CDC25A	P30304	993	3p21.31	59.09	human	57761916	Y59-p		LQGLGSDyEQPLEVK	27485204	1	0	0		High Cdc25A pY59 levels indicate poor prognosis.
prostate cancer	increased	DBN1	DBN1	Q16643	1627	5q35.3	71.43	human	452446	S142-p		NGLARLSsPVLHRLR	28319065	4	83	28		
ovarian cancer	increased	HSF1	HSF1	Q00613	3297	8q24.3	57.26	human	455484	S326-p	Vert_HS_TF	SSVDTLLsPTALIDS	28415561	31	21	13		shorter overall survival (OS) 
melanoma skin cancer	increased	KARS	KARS	Q15046	3735	16q23.1	68.05	human	9392600	S207-p		PYEITLLsPCLHMLP	28394346	3	1	0		
colorectal cancer	increased	TP53RK	PRPK	Q96S44	112858	20q13.12	28.16	human	1981300	S250-p		RLRGRKRsMVG____	28412249	2	0	7		
glioma	increased	ACSS2	ACSS2	Q9NR19	55902	20q11.22	78.58	human	83970101	S659-p	AMP-binding_C	PGLPKTRsGKIMRRV	28552616	2	1	0		
chronic lymphocytic leukemia	increased	USP7	USP7	Q93009	7874	16p13.2	128.30	human	449238	S18-p		KAGEQQLsEPEDMEM	28418900	2	63	5		
ovarian cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447980	S807-p	Rb_C	PGGNIYIsPLKSPYK	28319064	63	43	112	8974; 8957; 8516; 4277; 9308; 11917	
ovarian cancer	increased	RB1	Rb	P06400	5925	13q14.2	106.16	human	447981	T356-p		DSFETQRtPRKSNLD	28319064	12	17	36		
Parkinson's disease	increased	UBA52-RPS27A-UBB-UBC	ubiquitin	P62988		2p16	8.56	human	9765472	S65-p	ubiquitin	DYNIQKEsTLHLVLR	26389970	18	11	0	62802; 37642; 70973	
HIBM	mutation of site	Gne	GNE	O35826	114711	5q22	79.23	rat	21335600	M712-p	ROK	ALLGAASmVLDYTTR	21873062	1	0	0		
Parkinson's disease		PINK1	PINK1	Q9BXM7	65018	1p36.12	62.77	human	23003808	T313-p	Pkinase	EGLGHGRtLFLVMKN	22238344	1	1	0		
breast cancer	mutation of site	ESR1	ER-alpha	P03372	2099	6q25.1-q25.2	66.22	human	448103	Y537-p		CKNVVPLyDLLLEML	27748765	9	0	0		mutated in breast cancer, CRISPR-Cas9 genome editing mutation Y537S. 
cervical cancer	increased	PLK1	PLK1	P53350	5347	16p12.2	68.25	human	62370600	Y425-p	POLO_box	SDKYGLGyQLCDNSV	27899378	1	1	0		higher  PLK1  tyrosine  phosphorylation show  a  poor  5-year  survival  rate
colorectal cancer	increased	TCF3	E2A	P15923	6929	19p13.3	67.60	human	15500103	S39-p		NGKGRPAsLAGAQFG	26212009	1	2	1		
cardiomyopathy	increased	DNM1L	DRP1	O00429	10059	12p11.21	81.88	human	454690	S616-p		PIPIMPAsPQKGHAV	27739424	21	74	114	3455; 4494	
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357900	S13-p		SLVSSRPsSPEPDDL	28355568	3	2	0		
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357903	S10-p		SDASLVSsRPSSPEP	28355568	3	2	0		
glioma	increased	Olig2	OLIG2	Q9EQW6	50913	16 C3.3|16 52.6 cM	32.41	mouse	18357901	S14-p		LVSSRPSsPEPDDLF	28355568	3	2	0		
schizophrenia; bipolar disprder	increased	SP4	SP4	Q02446	6671	7p15.3	81.98	human	17548374	S770-p		VAAISQDsNPATPNV	26049820	3	4	0		in BD cerebellum postmortem, in cerebellum schizophrenia postmortem
ovarian epithelial carcinoma	increased	PRKAA1	AMPKA1	Q13131	5562	5p13.1	64.01	human	448786	T183-p	Pkinase	SDGEFLRtSCGSPNY	26068970	207	14	33	5256; 2535; 4188; 50081; 2531	spheroids
ovarian epithelial carcinoma	increased	STK11	LKB1	Q15831	6794	19p13.3	48.64	human	448147	S428-p		SSKIRRLsACKQQ__	26068970	25	2	3	3482	spheroids
PAH	increased	CAPN2	CAPN2	P17655	824	1q41	80.00	human	451162	S50-p	Peptidase_C2	GTLFQDPsFPAIPSA	26248159	3	1	0		
PAH	decreased	CAPN2	CAPN2	P17655	824	1q41	80.00	human	451303	S369-p	Calpain_III	DGNWRRGsTAGGCRN	26248159	2	1	2		
melanoma skin cancer	increased	ATM	ATM	Q13315	472	11q22.3	350.69	human	448797	S1981-p		SLAFEEGsQSTTISS	26275218	166	22	4	13050; 4526; 5883	nuclear S1981 is associated with melanoma progression, strong S1981 was associated with worse overall survival 
pancreatic carcinoma	increased	PIP5K1C	PIP5K1C	O60331	23396	19p13.3	73.26	human	486321	Y639-p		DAPATDIyFPTDERS	28388589	3	0	0		
breast ductal carcinoma	increased	AR	AR	P10275	367	Xq12	99.19	human	452166	S516-p		VSRVPYPsPTCVKSE	28415597	8	3	0		improved cancer-specifc survival in ductal breast cancer 
breast cancer, triple negative	increased	AR	AR	P10275	367	Xq12	99.19	human	452166	S516-p		VSRVPYPsPTCVKSE	28415597	8	3	0		poorer patient survival
breast ductal carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447542	T202-p	Pkinase	HDHTGFLtEYVATRW	28415597	1152	99	2017	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447594	Y187-p	Pkinase	HTGFLTEyVATRWYR	28415597	1124	149	4003	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK3	ERK1	P27361	5595	16p11.2	43.14	human	447543	Y204-p	Pkinase	HTGFLTEyVATRWYR	28415597	1175	128	3549	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	improved cancer-specifc survival in ductal breast cancer 
breast ductal carcinoma	increased	MAPK1	ERK2	P28482	5594	22q11.22	41.39	human	447593	T185-p	Pkinase	HDHTGFLtEYVATRW	28415597	1102	117	2416	9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474	improved cancer-specifc survival in ductal breast cancer 
NAFLD	increased	Sirt1	SIRT1	Q923E4	93759	10|10 B4	80.37	mouse	6006904	S164-p		DDRTSHAsSSDWTPR	28533219	1	4	0		
NAFLD	increased	SIRT1	SIRT1	Q96EB6	23411	10q21.3	81.68	human	6006904	S172-p		EDRASHAsSSDWTPR	28533219	1	4	0		
type 2 diabetes	increased	Cacna1c	CACNA1C iso5	Q0PCR6	12288	6 F1|6 55.86 cM	243.37	mouse	455278	S1927-p	CAC1F_C	ASLGRRAsFHLECLK	28119464	28	2	0		
breast cancer; obesity, hyperphagic		SMAD4	SMAD4	Q13485	4089	18q21.2	60.44	human	449628	T277-p		GSRTAPYtPNLPHHQ	28115363	3	0	0		
Alzheimer's disease	increased	PSEN1	PSEN1	P49768	5663	14q24.2	52.67	human	452183	S310-p	Presenilin	PEAQRRVsKNSKYNA	28132667	2	0	0		
breast cancer	increased	CDK4	CDK4	P11802	1019	12q14.1	33.73	human	448476	T172-p	Pkinase	YSYQMALtPVVVTLW	28566333	8	3	3		CDK4 T172 phosphorylation best correlated with sensitivity to PD0332991
pancreatic cancer	increased	AKT1	Akt1	P31749	207	14q32.33	55.69	human	447855	S473-p	Pkinase_C	RPHFPQFsYSASGTA	28363942	1396	18	44	88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694	
FMD	increased	FLNA	FLNA	P21333	2316	Xq28	280.74	human	451357	S2152-p	Filamin	TRRRRAPsVANVGSH	28348077	16	78	999	4761	
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	448278	S129-p	Synuclein	NEAYEMPsEEGYQDY	28636593	42	5	0	23706	
Parkinson's disease	increased	SNCA	SNCA	P37840	6622	4q22.1	14.46	human	3546424	Y39-p	Synuclein	KTKEGVLyVGSKTKE	28636593	4	2	11		
non-small cell lung cancer	increased	SCD	SCD	O00767	6319	10q24.31	41.52	human	3411245	Y55-p		PDIKDDIyDPTYKDK	28724430	1	2	6		poor prognosis
non-small cell lung cancer	increased	EGFR	EGFR	P00533	1956	7p11.2	134.28	human	448057	Y1092-p		TFLPVPEyINQSVPK	28724430	114	27	352	2236; 3777; 2234; 14565; 8543	poor prognosis
prostate cancer	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	394748800	K513-ub	PI3K_P85_iSH2	KEYIEKFkREGNEKE	28676490	1	1	0		
prostate cancer	increased	PIK3R1	PIK3R1	P27986	5295	5q13.1	83.60	human	394748801	K519-ub	PI3K_P85_iSH2	FKREGNEkEIQRIMH	28676490	1	1	0		
clear cell kidney cancer	increased	PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	448506	Y536-p		QKGQESEyGNITYPP	28692056	16	24	637		advanced pathologic stage
Alzheimer's disease	increased	LGMN	LGMN	Q99538	5641	14q32.12	49.41	human	183811000	S226-p	Peptidase_C13	CYYDEKRsTYLGDWY	28826672	1	0	0		
Alzheimer's disease	increased	SRPK2	SRPK2	P78362	6733	7q22.3	77.53	human	483237	T492-p		PSHDRSRtVSASSTG	28826672	2	6	0		
breast cancer; ovarian cancer	increased	EZH2	EZH2	Q15910	2146	7q36.1	85.36	human	34490427	T311-p		NTYKRKNtETALDNK	29351847	1	1	0	27888	better survival
rheumatoid arthritis; SLE	increased	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	454019	S591-p		DKEKNKGsLKRK___	28811476	8	2	15		biomarker of lupus nephritis activity
nephrosis	increased	Ptpn6	SHP-1	P29351	15170	6 F2|6 59.17 cM	67.56	mouse	448506	Y536-p		QKGQESEyGNITYPP	28811476	16	24	637		protects mice against lethal nephritis
nephrosis	increased	PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	448506	Y536-p		QKGQESEyGNITYPP	28811476	16	24	637		protects mice against lethal nephritis
SLE		PTPN6	SHP-1	P29350	5777	12p13.31	67.56	human	454019	S591-p		DKEKSKGsLKRK___	28811476	8	2	15		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449081	S396-p		GAEIVYKsPVVSGDT	28814543	116	41	90	9632	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	447928	S202-p		SGYSSPGsPGTPGSR	28814543	105	49	116	39357	
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449082	S404-p		PVVSGDTsPRHLSNV	28814543	102	48	69	35834; 20194	
Alzheimer's disease	increased	JUN	Jun	P05412	3725	1p32.1	35.68	human	447686	S63-p	Jun	KNSDLLTsPDVGLLK	28814543	110	41	4	9261; 5464; 2361	
Huntington's disease	decreased	HTT	Huntingtin	P42858	3064	4p16.3	347.60	human	10206804	T3-p		_____MAtLEKLMKA	29162692	7	1	0		
hepatocellular carcinoma	increased; mutation of site	TP53	p53	P04637	7157	17p13.1	43.65	human	394791401	R249-p	P53	CMGGMNRrPILTIIT	29225033	1	0	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469500	S254-p		PGEPTSRsQGEDCVM	29763855	1	0	0		
Alzheimer's disease	increased	Set	SET iso2	Q9EQU5-2	56086	2|2 B	32.10	mouse	6308300	S9-p		SAPTAKAsKKELNSN	29760653	5	2	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469501	T314-p		DPDGRLPtPSAPLHS	29763855	1	0	0		
chronic lymphocytic leukemia	increased	FCER2	FCER2	P06734	2208	19p13.2	36.47	human	1109469502	S265-p		DCVMMRGsGRWNDAF	29763855	1	0	0		
acute myelogenous leukemia	increased	RPS6KB1	p70S6K	P23443	6198	17q23.1	59.14	human	448607	T412-p	Pkinase_C	NQVFLGFtYVAPSVL	18056483	361	6	1	9209; 9206; 97596; 9234; 9205	
glioblastoma	increased	AXL	AXL	P30530	558	19q13.2	98.34	human	451490	Y779-p	Pkinase_Tyr	ADCLDGLyALMSRCW	28881571	2	1	2		significantly shorter overall survival
Alzheimer's disease	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
ADLB	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
DLB	decreased	YWHAQ	14-3-3 theta	P27348	10971	2p25.1	27.76	human	456053	S232-p		LTLWTSDsAGEECDA	28695147	4	16	0		Triton X-100 insoluble fraction; associated with clinical and pathological severity
diabetes mellitus	decreased	Fscn1	fascin	Q61553	14086	5 G2|5 81.84 cM	54.51	mouse	450888	S39-p	Fascin	KVNASASsLKKKQIW	28855604	11	12	0		patients with diabetic nephropathy
colorectal cancer	increased	HNRNPA1	hnRNP A1	P09651	3178	12q13.13	38.75	human	455946	S6-p		__MSKSEsPKEPEQL	29344170	2	93	4		poor prognosis
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	29298849	86	37	14		colocalization of pT175 tau with the active pGSK3B
CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	29298849	8	8	0		colocalization of pT175 tau with the active pGSK3B
ALS; CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449077	T175-p		ATRIPAKtPPAPKTP	29298849	8	8	0		CTE with ALS
ALS; CTE	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449079	T231-p		KKVAVVRtPPKSPSS	29298849	86	37	14		CTE with ALS
ALS	mutation of site	CCNF	CCNF	P41002	899	16p13.3	87.64	human	288031702	S621-p		GYEGDQEsEGEKEGD	29021214	1	1	0		
TBI		Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	29298849	74	125	4206		colocalized
CTE	increased	Gsk3b	GSK3B	P18266	84027	11q21	46.74	rat	448569	Y216-p	Pkinase	RGEPNVSyICSRYYR	29298849	74	125	4206		colocalization of pT175 tau with the active pGSK3B
PAH	increased	PDHA1	PDHA1	P08559	5160	Xp22.12	43.30	human	448258	S293-p	E1_dh	TYRYHGHsMSDPGVS	29070699	75	105	675	31866	
glioblastoma	increased	ATG4B	ATG4B	Q9Y4P1	23192	2q37.3	44.29	human	470896	S383-p		RLERFFDsEDEDFEI	29232556	2	37	2		
acute myelogenous leukemia	increased	MEF2C	MEF2C	Q06413	4208	5q14.3	51.22	human	474086	S222-p		GYGNPRNsPGLLVSP	29431698	1	32	1		AML chemotherapy resistance 
diabetes mellitus	decreased	CRYAA	CRYA1	P02489	1409	21q22.3	19.91	human	452108	T148-p	HSP20	FCGPKIQtGLDATHA	29467334	2	5	0		
diabetes mellitus	decreased	Cryaa	CRYA1	P24622	12954	17 B1|17 17.09 cM	22.49	mouse	452108	S171-p	HSP20	FSGPKVQsGLDAGHS	29467334	2	5	0		
glioblastoma	increased	TRIM9	TRIM9 iso5	Q9C026-5	114088	14q22.1	61.35	human	1046182900	S76-p		SLYSEADsGYGSYGG	29669288	1	0	0		stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression
glioblastoma	increased	TRIM9	TRIM9 iso5	Q9C026-5	114088	14q22.1	61.35	human	1046182901	S80-p		EADSGYGsYGGFASA	29669288	1	0	0		stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression
glioblastoma	increased	AXL	AXL	P30530	558	19q13.2	98.34	human	458360	Y698-p	Pkinase_Tyr	FGLSKKIyNGDYYRQ	28881571	1	3	52	44463	significantly shorter overall survival
pancreatic ductal adenocarcinoma	increased	IRAK4	IRAK4	Q9NWZ3	51135	12q12	51.53	human	2045325	T345-p	Pkinase_Tyr	KFAQTVMtSRIVGTT	29363544	6	3	0	12914; 87995; 80738; 11927	
pancreatic ductal adenocarcinoma	increased	RELA	NFkB-p65	Q04206	5970	11q13.1	60.22	human	447800	S536-p		SGDEDFSsIADMDFS	29363544	137	4	0	4887; 3036; 5733; 3031; 4886; 4025; 3033; 13346	
psoriasis	increased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447993	T573-p	Pkinase	AENGLLMtPCYTANF	29290690	17	16	180	9346	increase in western blot and in nuclei in lesion skin
psoriasis	decreased	RPS6KA1	p90RSK	Q15418	6195	1p36.11	82.72	human	447990	S380-p	Pkinase_C	HQLFRGFsFVATGLM	29290690	53	47	64	13397; 13588; 9341; 9335; 12032; 11989; 13575	increase in western blot and cytosolic in lesion skin
psoriasis	increased	RPS6KA3	RSK2	P51812	6197	Xp22.12	83.74	human	450152	T577-p	Pkinase	AENGLLMtPCYTANF	29290690	9	14	180		increase in western blot and in nuclei in lesion skin
psoriasis	decreased	RPS6KA3	RSK2	P51812	6197	Xp22.12	83.74	human	448065	S386-p	Pkinase_C	HQLFRGFsFVAITSD	29290690	11	18	59	13397; 13588; 9341; 9335; 12032; 11989; 13575	increase in western blot and cytosolic in lesion skin
HBL	decreased	Cebpa	C/EBP-alpha	P53566	12606	7 B2|7 21.02 cM	37.43	mouse	457552	S193-p		PPPHPHAsPAHLAAP	29159818	12	0	0		C/EBPa-dependent CSCs are observed in patients with aggressive hepatoblastoma and in patients with a predisposition for liver cancer. 
HBL	decreased	CEBPA	C/EBP-alpha	P49715	1050	19q13.11	37.56	human	457552	S190-p		PPPPPPPsHPHPHPP	29159818	12	0	0		C/EBPa-dependent CSCs are observed in patients with aggressive hepatoblastoma and in patients with a predisposition for liver cancer. 
lung cancer	increased	HMGA1	HMGA1	P17096	3159	6p21.31	11.68	human	452256	S99-p		KEEEEGIsQESSEEE	29038488	5	60	173		involved in lung cancer cell proliferation
breast cancer		HMMR	HMMR	O75330	3161	5q34	84.10	human	460367	T703-p	HMMR_C	KENFALKtPLKEGNT	28993511	1	10	6		predictor  of  breast  cancer-specific  survival  and  relapse-free  survival  in  patients  with  estrogen  receptor (ER)-negative breast cancer
pancreatic cancer	increased	MAPRE1	EB1	Q15691	22919	20q11.21	30.00	human	59049802	T206-p		QVNVLKLtVEDLEKE	29228685	3	1	0		correlated with high ASK1 expression; ASK1-mediated phosphorylation of EB1 may contribute to pancreatic cancer cell proliferation 
FHC	increased	Ryr2	RYR2	E9Q401	20191	13 A1|13 4.38 cM	564.82	mouse	458801	S2813-p		ISQTSQVsIDAAHGY	29402414	43	6	5		spontaneous Ca 2? transients (sCaTs) 
hepatocellular carcinoma	increased	SREBF1	SREBP-1	P36956	6720	17p11.2	121.68	human	900975702	T59-p		AGSGAGGtDPASPDT	29514980	1	0	0		T59  phosphorylation is correlated with poor prognosis in HCC patients.
colonic inflamation	increased	Trim28	TIF1B	Q62318	21849	7|7 A1	88.85	mouse	452391	S473-p		SGMKRSRsGEGEVSG	29487189	16	111	20		
colonic inflamation	increased	Map3k3	MEKK3	Q61084	26406	11|11 E1	70.78	mouse	468184	S337-p		DPRGRLRsADSENAL	29487189	2	31	46		
colonic inflamation	increased	Pak1	PAK1	O88643	18479	7 E1|7 53.57 cM	60.74	mouse	448170	S144-p		SNSKKYMsFTDKSAE	29487189	17	27	138	2606	
colonic inflamation	increased	Pak2	PAK2	Q8CIN4	224105	16 B2|16 22.4 cM	57.93	mouse	448295	S141-p		TVKQKYLsFTPPEKD	29487189	10	81	76	2606	
colorectal carcinoma	increased	STRAP	STRAP	Q9Y3F4	11171	12p12.3	38.44	human	11267002	T175-p		LWDHATMtEVKSLNF	29783958	3	1	0		
colorectal carcinoma	increased	MELK	MELK	Q14680	9833	9p13.2	74.64	human	2861400	S171-p	Pkinase	HLQTCCGsLAYAAPE	29783958	2	0	0		
colorectal carcinoma	increased	MELK	MELK	Q14680	9833	9p13.2	74.64	human	456039	T167-p	Pkinase	NKDYHLQtCCGSLAY	29783958	3	1	0		
colorectal carcinoma	increased	STRAP	STRAP	Q9Y3F4	11171	12p12.3	38.44	human	11267003	S179-p		ATMTEVKsLNFNMSV	29783958	3	0	0		
T cell lymphoma	increased	MAP3K7	TAK1	O43318	6885	6q15	67.20	human	7444663	T444-p		RRSIQDLtVTGTEPG	29511289	1	6	0		
CCA	increased	SP1	SP1	P08047	6667	12q13.13	80.69	human	452233	S59-p		GGQESQPsPLALLAA	28574228	5	16	0		
breast cancer	increased	LDHA	LDH-A	P00338	3939	11p15.1	36.69	human	454712	Y10-p		TLKDQLIyNLLKEEQ	28218905	3	24	374	8176	progression of metastatic cancer
lung cancer	decreased	ZNF322	ZNF322A	Q6U7Q0	79692	6p22.2	46.94	human	31086030	S391-p		SEKGLELsPPHASEA	28581525	1	1	0		
Alzheimer's disease	increased	MAPT	Tau iso8	P10636-8	4137	17q21.31	45.85	human	449328	S324-p	Tubulin-binding	KVTSKCGsLGNIHHK	28760828	8	6	2		
Status epilepticus	increased	Eif4b	EIF4B	Q5RKG9	300253	7q36	69.06	rat	452271	S504-p		SSDTEQPsPTSGGGK	28874824	2	53	22		animal model of epilepsy
Alzheimer's disease	decreased	BACE1	BACE	P56817	23621	11q23.3	55.76	human	450178	S498-p		DDFADDIsLLK____	28946017	6	3	0		decreased in AD brains
medulloblastoma	increased	Atoh1	ATOH1	P48985	11921	6 C1|6 30.03 cM	37.85	mouse	386186604	Y78-p		CTARAAQyLLHSPEL	29168692	1	1	0		
Alzheimer's disease	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	22996309	S358-p	Pkinase_Tyr	ELRKTQTsMSLGTTR	28758999	12	1	0	91689; 37333	
Alzheimer's disease	increased	MLKL	MLKL	Q8NB16	197259	16q23.1	54.48	human	5891858	T357-p	Pkinase_Tyr	FELRKTQtSMSLGTT	28758999	5	0	1		
neuroblastoma	increased	ROCK2	ROCK2	O75116	9475	2p25.1	160.90	human	484404600	T396-p		DDKGDVEtFPIPKAF	28739902	1	0	0		
hypertrophic cardiomyopathy	increased	PPP2R5D	PPP2R5D	Q14738	5528	6p21.1	69.99	human	457390	S573-p		KVLLRRKsELPQDVY	29294329	6	51	347		S573 is increased in the setting of pressure overload-induced cardiac hypertrophy.
hypertension	increased	Grin2b	NMDAR2B	Q00960	24410	4q43	166.07	rat	450171	S1303-p	NMDAR2_C	NKLRRQHsYDTFVDL	28972129	35	11	31		increased phosphorylation in the hypothalamic paraventricular nucleus (PVN), but not in the hippocampus and frontal cortex,
non-small cell lung cancer	increased	GLS	glutaminase iso3	O94925-3	2744	2q32.2	65.46	human	937769500	S314-p		RYVGKEPsGLRFNKL	29515166	1	0	0		poor survival of NSCLC patients
T cell lymphoma	increased	MAP3K7	TAK1	O43318	6885	6q15	67.20	human	969328000	T344-p		QVPATNDtIKRLESK	29511289	1	1	0		
